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Abstract 
 
My research investigated the distribution of antimicrobial peptides (cathelicidin 
and β-defensin 2), vitamin D and the inflammatory marker procalcitonin, between 
systemic and localised respiratory levels in stable bronchiectasis patients. 
Bronchiectasis is a localised chronic lung disease that is characterised by acute 
reoccurring lower tract respiratory infections. Non-cystic fibrosis bronchiectasis 
patient serum and sputum samples were collected as part of an ongoing clinical 
trial. This trial is investigating the usefulness of Tiotropium for the treatment of 
bronchiectasis.  
 
Antimicrobial peptides are a fundamental component of the innate immune 
system. The innate immune system is vital in providing the first line of defence 
against pathogens. At epithelia sites this is more so, as cells are often in direct 
contact with the environment. Both cathelicidin and β-defensin 2 expression has 
been found to be upregulated by the active vitamin D metabolite, 1,25-
dihydroxyvitamin D. This research also aimed to determine if vitamin D 
deficiency is prevalent in bronchiectasis, and how these levels correspond with 
cathelicidin and hBD-2. Lastly, whether procalcitonin, a known inflammatory 
marker of bacterial infections is a suitable biomarker for bronchiectasis. Other 
inflammatory markers have been shown to be consistently elevated in stable 
bronchiectasis patients.  
 
The use of commercial ELISA kits demonstrated the notion of systemic levels not 
being representative of localised levels. Both of the antimicrobial peptides, 
cathelicidin and β-defensin 2, show elevated sputum levels consistent with 
bronchiectasis being a localised condition. Contrastingly, vitamin D metabolites 
are found to be lower in the airways. This is predicted to be due to the majority of 
vitamin D metabolites being protein bound in circulation, thereby affecting their 
tissue distribution. Stable bronchiectasis patients do not have persistently elevated 
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serum procalcitonin levels but procalcitonin levels are significantly higher in the 
sputum.   
 
Our findings report that suboptimal vitamin D levels, but not vitamin D deficiency, 
were prevalent in stable bronchiectasis patients. No correlations were found 
between 25-hydroxyvitamin D and antimicrobial peptide concentrations, 
consistent with other studies findings. However, localised levels of the active 
form, 1,25-dihydroxyvitamin D, were correlated with localised cathelicidin 
(CAMP) levels but not β-defensin 2.  
 
Future work should focus on the hormonal form, 1,25-dihydroxyvitamin D, if an 
in vivo association with antimicrobial peptides is to be found. A number of factors 
can influence vitamin D bioavailability, including, known single nucleotide 
polymorphisms in the vitamin D receptor and vitamin D binding protein.     
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Chapter One: Introduction and 
Literature Review 
 
1.1 Bronchiectasis 
Laennec first described the existence of bronchiectasis in 1819 [1]. Bronchiectasis 
has since been defined as a chronic lung disease that can be characterised by the 
persistent dilatation of the bronchi [2]. Common symptoms of bronchiectasis 
include a persistent cough, purulent mucus production, dyspnoea (breathlessness), 
haemoptysis (coughing up of blood), wheezing, crackles, chest pain, weight loss, 
rhinosinusitis, finger clubbing and general fatigue [3, 4]. 
 
Patients living with bronchiectasis experience reoccurring lower tract respiratory 
infections (LTRI’s) due to their increased susceptibility to infection and microbial 
colonization [5, 6]. These exacerbations often require frequent hospitalization and 
cause progressive loss of lung function [7]. Sufferers live with a high level of 
morbidity and have a high risk of premature mortality [6, 8-10]. A New Zealand 
study reported a mortality rate in bronchiectasis patients of 21% (32/152) over 
twelve months [10]. A  Finnish study of 842 individuals (diagnosed in 1982-1986) 
revealed a mortality rate of 28% (longest follow up period was 12.9 years) [6]. 
Bronchiectasis is a significant burden on those it affects, greatly limiting their 
quality of life [6].  
 
1.1.1 Exacerbations 
There is no standardized definition of an exacerbation available for bronchiectasis 
[11, 12]. Bronchiectasis exacerbations are commonly compared to chronic 
obstructive pulmonary disorder (COPD), usually using increased breathlessness 
and purulent sputum production as indicators [11]. Typically an exacerbation is 
any period of deterioration seen in respiratory condition [13]. Exacerbations often 
present as a worsening of the broad symptoms, for example, increased sputum 
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production, deteriorated cough or change in cough character [14]. The definition 
of exacerbations for adults is different from that required for children [15]. Severe 
exacerbations will require hospitalization and the use of intravenous or oral 
antibiotics [16]. The rate of hospitalizations due to exacerbations is increasing. 
The average US hospitalisation rate for bronchiectasis from the years 1993 to 
2006 is 16.5/100,000 and has increased approximately 3% every year [17].  
 
Research indicates an exacerbation rate of 1.5-6.5 per year for bronchiectasis 
patients [18, 19]. A contemporary study of 152 patients showed there was a total 
of 307 exacerbations, of which at least 46% were readmitted within another 
exacerbation in the year [10]. Another 2009 study identified 115 exacerbations in 
30 children during their study period. This gave a rate of 1.6 exacerbations per 
year, of which 35% of exacerbations required hospitalization and treatment with 
intravenous antibiotics [16]. Currently there is an absence of specific 
bronchiectasis measures for exacerbations. This presents a need for serum or 
sputum biomarkers to be identified, to aid in the monitoring of exacerbations [11].  
 
1.1.2 Diagnosis 
Bronchiectasis is often difficult to diagnose and therefore is commonly 
misdiagnosed [4, 20]. Bronchiectasis most often gets mistaken for other common 
respiratory conditions, for example, asthma or COPD. A delay usually exists 
between the onset of bronchiectasis and a confirmed diagnosis. One 
bronchiectasis phenotyping study has shown a delay in diagnosis of 17 years. The 
mean age of diagnosis was 54 years, yet the mean age of onset of symptoms was 
37 years [21]. Symptoms often first present themselves in childhood; however a 
diagnosis is often not obtained until adulthood.  
 
The current ‘gold standard’ for diagnosis is the use of high resolution computed 
tomography (HRCT) scans [3, 22]. This is a non-invasive procedure [23] used to 
confirm the dilation and thickening of bronchial walls, as seen in Figure 1 [3]. 
HRCT confirms bronchiectasis if the bronchi are internally dilated by more than 
1.5 times the pulmonary artery size [23, 24]. The HRCT scan will identify a lack 
airway tapering [23], thickened bronchial walls, airway constrictions and cysts at 
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the bronchial end points [3]. These abnormalities can similarly indicate the 
occurrence of bronchiectasis. Even now with the availability of HRCT scans, the 
overall diagnosis of bronchiectasis is still poor in both developed and developing 
countries [14]. 
 
 
Figure 1 High-resolution computed tomographic (HRCT) image of bronchiectasis lungs 
showing dilated and thickened airways, as published by Barker, 2002 [3] 
 
1.1.3 Pathophysiology 
Bronchiectasis arises due to a pattern of continual cycles of infection, followed by 
periods of persistent inflammation in the airways. This ‘vicious cycle’, a term 
coined by Coles in 1986, is a chain of events that leads to progressive damage of 
connective tissue and cilia within the bronchi. This destruction leads to the 
general obstruction of smaller airways and affects the mucociliary-clearance 
function. Thus the lungs lose their vital natural protective mechanisms, placing 
them at risk of pathogen growth and colonization. This cycle occurs after an initial 
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insult which can either be environmental, congenital or as a result of immune 
defects [5].  
 
Coles ‘vicious cycle’ is a host-facilitated phenomenon and works on the principle 
that inflammation has the potential to be both, beneficial and detrimental. 
Normally inflammation is a brief controlled response upon exposure to foreign 
material that is used to provide a line of protection. But if elimination of the 
pathogen is not successful, then this can lead to chronic inflammation. Chronic 
inflammation limits the repair response of the lungs, thereby allowing damage to 
occur in healthy tissue. This cycle results in the permanent dilatation of the 
bronchi [5]. 
 
 
Figure 2 The ‘vicious cycle’ hypothesis of bronchiectasis, as published by Chalmers et al., 
2013 [5, 25] 
 
Bronchiectasis is a regarded as a neutrophil driven disease [25, 26]. During each 
exacerbation, particularly in severe ones, neutrophils migrate to the respiratory 
tract. This recruitment of neutrophils is stimulated by chemoattractants, for 
example, interleukin 8, tumour necrosis factor-α or interleukin 1B (IL-1β). The 
neutrophils then act to increase the levels of proteolytic enzymes [25]. Studies 
show that both cytokines and proteolytic enzymes (eg. MMP-8 or elastase) have 
been found to be upregulated in stable bronchiectasis patients [25, 27-29]. It is the 
process of infection, neutrophilic inflammation and proteolytic enzymes that work 
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in a cycle to damage the airways, leading to the development of bronchiectasis 
[13]. This forms the ‘vicious cycle’ hypothesis of bronchiectasis (Figure 2). 
 
1.1.4 Prevalence/Incidence 
The prevalence of bronchiectasis appeared to be decreasing during the twentieth 
century, where the aforementioned became regarded as an ‘orphan’ disease [6, 13]. 
Recently a resurgence of bronchiectasis has been noted within certain 
communities [30]. There is very limited data available worldwide that has 
measured the prevalence and incidence of bronchiectasis. Understandably this 
makes comparing data from different prevalence studies difficult. The 
underestimation of bronchiectasis is a major issue, as most individuals are 
outpatients and often are misdiagnosed with COPD or asthma [4, 13]. The notion 
stands that bronchiectasis is a neglected and poorly understood condition, placing 
limitations on it management [14].  
 
A recent two year study of bronchiectasis in New Zealand children provides the 
most recent national prevalence rates. The investigation revealed an estimated 
national incidence rate of 3.7/100,000 per year, in children less than 15 years of 
age. This figure, due to study design, should be regarded as the minimum 
incidence figure. The only other comparable data available is the national 
incidence rate from a contemporary study of under 15 year olds in Finland. Their 
estimated incidence rate is 0.5/100,000 per year [31]. The New Zealand’s national 
incidence rate in under 15 year olds is seven times the national incidence rate in 
Finland. These two studies similarly highlight the concept that bronchiectasis 
most often develops during early childhood; but a recognised significant delay in 
diagnosis. 
 
Interestingly, the New Zealand study identified ethnic and regional variances in 
the incidence of bronchiectasis. An incidence of 17.8/100,000 in Pacific Island 
children and 4.8/100,000 in Maori children was reported. These incidences are 
twelve times and three times higher, respectively, than for NZ European children 
[9]. These ethnic findings were also supported by older New Zealand data 
reporting a prevalence of 1/6,000 children [32]. Similar findings have been 
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reported in other indigenous populations. A rate of 16/1,000 is reported in 
Southwest Alaskan Native Children from Yukon Kuskokwim Delta region [33]. 
Another study shows an incidence of 15/1,000 in central Australian Aboriginal 
children [34]. In both of these populations respiratory disease is the largest 
preventable cause of death in infants [33, 34]. Limited data is available for the 
prevalence of bronchiectasis in New Zealand adults [10]. 
 
Multiple studies have found a predisposition for the development of 
bronchiectasis in women and at the extremes of age [9, 23, 35]. Those greatest at 
risk are therefore elderly women [36]. In regards to the extremes of age, a US 
study has shown an increase from 4.2/100,000 in 18-34 year olds to 
271.8/100,000 in over 75 year olds [36]. The higher frequency of bronchiectasis 
in females is supported by the recent New Zealand incidence study, where 37 out 
of 65 participants were female [9]. Pasteur’s bronchiectasis pathogenesis study 
showed a larger majority of female (n=94) than male counterparts (n=56). 
Additionally in this study, females also had a higher mean age [23]. In 
Shoemark’s bronchiectasis aetiology research, a total of 65% of the participants 
were female [35]. There is an indication for a predisposition in women for the 
development of bronchiectasis; however the disease has been shown to progress 
equally in both sexes.  
 
Other global prevalence rates include the Hong Kong government estimate of 
16.4/100,000 in 1990 [13]. In the US 110,000 adults were determined to have 
bronchiectasis in a 2005 study [36].  Newer US data indicates a rate of 52/100,000 
at an additional cost of 1.1 billion dollars per annum [17].  This study also showed 
that the prevalence of bronchiectasis increasing by 8.7% per year between 2007 
and 2008 in the US [17]. Clearly, bronchiectasis prevalence is on the rise and 
should now be regarded as a ‘common’ disease worldwide [30].  
 
1.1.5 Aetiologies 
A substantial number of causes can be linked to the onset of bronchiectasis. 
Finding a causative factor is vital in the long-term management of the condition, 
as it has the potential to influence therapeutic options. There are a number of 
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papers investigating the pathogenesis of bronchiectasis [9, 21, 23, 35]. Many of 
these studies, shown in Table 1, involved specialist respiratory clinics [23, 35]. 
Consequently, these bronchiectasis cases are likely to be more complex than other 
studies, composed mainly of individuals struggling to control symptoms. These 
studies may not accurately represent stable bronchiectasis aetiologies [21, 35]. 
The recent phenotyping study by Anwar et al., 2013 has used a more generalised 
sample population, thereby reducing this bias [21].   
 
The majority of cases (50-80%) of bronchiectasis are deemed to be idiopathic; no 
known causative factor [23]. Most idiopathic instances are probably due to 
unknown immunological mechanisms. There is beginning to be a move away 
from focusing on extrinsic factors (eg. post-infection) to more intrinsic factors (eg. 
congenital, systemic or immunological) [23].  
 
Post-infection is the next most prevalent contributing factor in providing the 
initial insult for bronchiectasis. This includes various childhood respiratory 
conditions, for example, pneumonia, tuberculosis, whooping cough, adenovirus, 
complicated measles and pertussis [3, 4]. The contribution of these conditions is 
probably not as relevant today with immunizations and use of antibiotics, so will 
expect to see a fall in these causalities [3, 23]. Post-infection is still common in 
indigenous populations and non-affluent countries [14]. Socioeconomic factors 
may also contribute to these health inequalities. These include low immunisation 
rates, overcrowded housing and poor access to healthcare [9, 33].  
 
Congenital causes only make up a small proportion but often therapy can be taken 
in these instances. Cystic fibrosis (CF) is a well-known autosomal recessive 
disorder; most predominant in white populations with a rate of 1 in every 2500 
births [13]. Bronchiectasis is a significant factor in CF mortality [37]. This 
research is only focusing on non-cystic fibrosis bronchiectasis. Other congenital 
causes include α-1-antitrypsin (AAT) deficiency and allergic bronchopulmonary 
aspergillosis (ABPA) [13, 22]. ABPA is characterised as a hypersensitive 
response to the bacteria Aspergillus in the airways of asthmatics; can result in the 
development of bronchiectasis in the upper lobe of the lung [13].  
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Table 1 Comparison of existing phenotyping studies in bronchiectasis  
Aetiology Pasteur et al., 
2000 [23] 
Shoemark 
et al., 2007 
[35] 
Twiss et al., 
2012 [9] 
Anwar et 
al., 2013 
[21] 
 
Number of Patients 150 165 65 (<15 yo) 189 
Idiopathic 53% 26% 54% 43% 
Post-Infectious  29% 32% 22% 24% 
Immune Defects  8% 7% 6% 1% 
Cystic Fibrosis 3% 1% n/a <1% 
Young’s syndrome 3% 3% n/a <1% 
Ciliary 
dysfunction/PCD 
1.5% 10% (PCD) n/a 1% 
Aspiration/Gastro-
oesophageal reflux  
4% 1% 6% 1% 
Pan bronchiolitis <1% 2% n/a n/a 
Congenital Defect <1% n/a n/a n/a 
ABPA 7% 8% n/a 4% 
Rheumatoid Arthritis 3% 2% n/a 5% 
Ulcerative Colitis <1% 3% n/a 2% 
Yellow Nail Syndrome n/a 2% n/a n/a 
Mycobacterium 
infection 
n/a 2% n/a n/a 
Post-Oncology n/a n/a 11% n/a 
COPD n/a n/a n/a 12% 
Pink’s Disease n/a n/a n/a <1% 
AAT deficiency 0% n/a n/a 1% 
Asthma n/a n/a n/a 3% 
 
Congenital ciliary disorders can lead to the development of bronchiectasis, for 
example primary cilia dyskinesia (PCD) and Kartagener’s syndrome. PCD is a 
rare (1 in 15000-35000) autosomal recessive disorder that results in abnormally 
functioning cilia [38]. Cilia are vital structures located on mucosal surfaces, 
especially the respiratory tract. Their normal function is to beat and propel mucus, 
this helps to maintain a sterile airway environment. PCD therefore limits the 
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removal of debris and microorganisms, potentially leading to the development of 
bronchiectasis [3, 22]. 
 
Immune deficiencies or systemic conditions are beginning to be more associated 
with bronchiectasis, particularly in affluent countries [14]. Immunodeficiency is 
most often due to deficiencies in immunoglobulins (eg. IgG or IgM subclass 
deficiencies), humoral factors (eg. antibody deficiency or defective antibody 
response) or common variable immune deficiency (CVID) [3, 23, 35].  
 
Bronchiectasis is often the end path of various systemic and respiratory diseases 
[13]. Bronchiectasis is often diagnosed in patients with inflammatory bowel 
disease (IBD) including, Crohn’s disease, and ulcerative colitis; all of which are 
manifestations of the bowel [3]. The occurrence of bronchiectasis is also 
commonly associated with rheumatoid arthritis (a collagen vascular disease) [3, 
19, 21, 35]. Panbronchiolitis is an obstructive airway disease found predominantly 
in Japanese individuals that is determined by the presence of parenchymal nodules. 
Panbronchiolitis also know to contribute to the onset of bronchiectasis, 
particularly in Japanese populations [13]. 
 
Comorbidities are a common feature in bronchiectasis patients, especially asthma 
and COPD. In individuals with COPD it has been shown that up to 50% may also 
have bronchiectasis on CT scans [39].  In fact a combination of bronchiectasis and 
COPD represent a more severe phenotype [40]. Comorbidities are regarded as risk 
factors as they increase the chance of mortality [6]. Other aetiologies include 
aspiration or obstruction of foreign bodies. This can include gastric reflux, 
tumours, foreign bodies or enlarged lymph nodes [13].  
 
1.1.5.1 Pathogens 
Microbial organisms are commonly isolated from bronchiectasis individuals. King 
et al., 2007 study assessed the sputum of 89 clinically stable bronchiectasis 
patients. Initially the two most abundant pathogens were Haemophilus influenzae 
(47%) and Pseudomonas aeruginosa (12%) [41]; similar figures have been 
reported in a pathogenesis study of 35% and 31% respectively [23]. Meanwhile 
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21% of those studied had no pathogens isolated. Results remained fairly similar in 
follow up assessments, indicating chronic colonization; except for an increase in 
antibiotic resistance (from 13% up to 30%) [41]. Other isolated pathogens from 
bronchiectasis patients include Moraxella catarrhalis, Streptococcus pneumonia, 
Staphylococcus aureus and Nontuberculosis mycobacteria (NTM) [22, 41].  
 
Some studies have indicated an association between the severity of bronchiectasis 
and chronic colonization of Pseudomonas aeruginosa [23, 40, 41]. This pathogen 
is typically very difficult to eradicate. Studies show an observed increased 
exacerbation rate and a decreased lung function (%FEV1) in patients chronically 
colonized by Pseudomonas aeruginosa [23, 41]. Chronic colonization by 
Pseudomonas aeruginosa is a high risk factor for mortality [8]. Patients that had 
no pathogens isolated from their sputum tended to show the mildest form of 
disease, whilst those colonised by Pseudomonas aeruginosa the most severe [41].  
Remarkably pathogens are not found in all individuals, even during acute 
exacerbations. Often pathogens are still isolated in stable patients, indicating 
chronic colonisation. This shows the loss of sterility in the respiratory tract due 
failure of the immune system [26]. 
 
Determining the pathogenesis of bronchiectasis may be beneficial for the 
management and treatment of the disease [23]. Two individual studies have 
shown a diagnosis of aetiology to be beneficial in treatment of 15% [23] and 37% 
of bronchiectasis patients [35]. Treatment is particularly effective in those with 
congenital conditions. 
 
1.1.6 Management of Bronchiectasis 
Currently there is no standardized option for the treatment of bronchiectasis. 
Treatment plans for bronchiectasis are often an extrapolation from the treatment 
of other respiratory conditions, for example, CF, COPD and pneumonia [19, 42]. 
Planning treatment is often difficult due to the heterogeneric nature of 
bronchiectasis. There are very diverse phenotypes, some individuals will present 
with very few symptoms, whereas others experience symptoms daily [22]. There 
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is a need for understanding the heterogeneric nature of bronchiectasis in the 
development of new treatments [43]. 
 
Bronchiectasis can also be either focal or diffuse depending on the number of 
lobes and lung segments that are affected [3]. Bronchiectasis requires ongoing 
long-term management of the condition, aimed at reducing the frequency of 
exacerbations thereby removing the potential for further lung damage. The goal of 
treatment is to increase the overall quality of life for bronchiectasis sufferers [13].  
 
Treatment can only commence once diagnosis is confirmed by HRCT scan. Then 
determination of aetiology and severity of disease needs to be made. Factors often 
used to assess severity include, lung function decline (%FEV1), exacerbation 
frequency and changes in sputum colour, volume or microbiology [16, 44]. 
Health-related quality of life (HrQoL) questionnaires, for example, St George’s 
Respiratory Questionnaire and Leicester Cough Questionnaire, are also commonly 
used [4]. 
 
Lung function decline is typically monitored by measuring the forced expiratory 
volume in one second (%FEV1) of patients [3]. Studies have shown an estimated 
mean decline in %FEV1 of 33-55mL per year in patients with non-cystic fibrosis 
bronchiectasis [20, 35, 41, 44]. No long-term treatment has had any impact so far 
on the declining FEV1 in bronchiectasis.     
 
Current treatment is based on a combination of antibiotics, anti-inflammatories, 
chest physical therapy, and surgery [45]. Antibiotics are usually administered 
upon admittance for an exacerbation. There has been a move towards the use of 
oral antibiotics (eg. nebulised aminoglycoside) as they are more specific, rather 
than intravenous antibiotics [45]. Recommendations exist for a more 
individualized approach for patients, by culturing the sputum and selecting 
antibiotics based on results [22]. But not all patients have microorganisms isolated 
from their sputum [13]. Very limited randomised controlled trials exist for 
antibiotics in bronchiectasis [45].     
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There is the possibility for the use of prophylactic antibiotics, particularly for 
stable bronchiectasis patients. This aims to reduce their bacterial burden; thereby 
breaking the ‘vicious cycle’ [45]. Very limited evidence is available to support 
this approach [19]. Using prophylactic oral antibiotics has been shown to reduce 
the effectiveness of oral antibiotics during an exacerbation [16]. 
 
Anti-inflammatories (eg. inhaled corticosteroids or oral macrolides) help to reduce 
the amount of structural damage done to airways, by suppressing the 
inflammatory response [13, 22]. A recent randomised double-blind trial was 
undertaken in New Zealand using the macrolide antibiotic Azithromycin [46]. 
This drugs works via its anti-inflammatory and immunomodulatory properties. 
Findings showed an exacerbation rate of 0.59 per patient in the Azithromycin 
group and 1.57 per patient in the placebo group. This data therefore indicates the 
usefulness of Azithromycin in reducing frequency of exacerbations. Care though 
needs to be taken to prevent the development of macrolide resistance [46].  
 
Commonly used is chest physical therapy for clearance of sputum from the 
airways. Surgery or lung transplant are reserved for very end-stage bronchiectasis; 
therefore only considered if bronchiectasis is focal, resistant or no longer 
responding to aggressive medical therapy [4, 45]. 
 
Significantly more research is needed in the development of suitable long-term 
treatments for bronchiectasis individuals. The heterogeneric nature of 
bronchiectasis suggest that treatment should become more individualized, for 
example, culturing sputum and selecting antibiotics based on microbes isolated 
[43]. Additionally, it would be beneficial if specific biomarkers were identified to 
guide therapy during exacerbations [4]. Prevention and early diagnosis should be 
the focus of future treatment options [9].  
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1.2 Vitamin D 
1.2.1 Physiology 
Vitamin D is classified within the family of secosteroid hormones [47]. Vitamin D 
exists in two main forms: cholecalciferol (vitamin D3) and ergocalciferol (vitamin 
D2) [47, 48]. The predominant source of vitamin D is from sun exposure (90%) 
and the minority from diet (5-10%), either through an oily fish diet or 
supplementation [49]. Limited foods naturally contain vitamin D; therefore many 
foods are now fortified yet currently not in New Zealand [50].  
 
The two main forms of vitamin D are biologically inactive and will undergo two 
sequential hydroxylation steps to become active [51, 52]. Vitamin D3 is produced 
by 7-dehydrocholesterol by thermal isomerization upon exposure to UVB 
radiation on the skin [53]. Vitamin D3 can then enter the circulation where it is 
bound to vitamin D binding protein (DBP) for transportation. DBP is the highest 
affinity binder of the vitamin D analogues; albumin acts as a low affinity carrier 
[54, 55].  
 
Hydroxylation occurs in the liver, at position 25 of vitamin D3, by the enzyme 25-
hydroxylase (CYP27A1 or CYP2R1) to form 25-hydroxyvitamin D3 (25(OH)D3) 
[56]. This is the major circulating form of vitamin D, used to determine vitamin D 
status [49]. Further hydroxylation occurs in the kidney by 25-hydroxyvitamin D-
1α-hydroxylase (CYP27B1) to form 1,25-dihydroxyvitamin D3 (1,25(OH)2D3-
calcitriol); the active vitamin D metabolite (Figure 3) [57]. This renal production 
is tightly regulated by levels of parathyroid hormone (PTH), calcium and 
phosphorus [58, 59]. There are over 50 known vitamin D metabolites [60]. 
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Figure 3 The synthesis, bioactivation and inactivation of vitamin D3, as published by Dusso, 
2005 [61] 
 
1.2.2 Classical Function  
The association between sunlight and skeletal health has long been known. Most 
notably at the beginning of the twentieth century, when there was widespread 
incidence of children with nutritional rickets and growth retardation. This arose 
predominantly during the industrial revolution in Europe, where the excessive 
pollution greatly reduced children’s exposure to sunlight. The earliest description 
of rickets was by Whistler in the 1600s, and later on by Glisson in 1951 [59]. 
Rickets is the result of insufficient calcium intake that effects bone development 
causing weakened, deformed bones and muscle spasms [59, 62]. The use of UV 
light for the treatment of rickets was commonly used, as demonstrated by 
Shiadecki in 1822, and later on by Hess and Unger [59, 62, 63]. But it was 
sometime before the molecule vitamin D was identified in this association [64]. 
  
The primary role of vitamin D is in bone homeostasis via the renal production of 
1,25-dihydroxyvitamin D (1,25(OH)2D).  Maintaining calcium-phosphate 
homeostasis is vital for preserving bone health. Calcium is required to be 
maintained within a narrow concentration range, otherwise bone reabsorption 
results, leading to bone mineralisation [49, 65]. 
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Vitamin D deficiency (VDD) therefore has numerous effects on skeletal health. 
Serious VDD traditionally results in rickets, osteomalacia or osteoporosis [48, 65]. 
When vitamin is insufficient it can result in hypovitaminosis D, causing reduced 
calcium absorption leading to secondary hyperparathyroidism. Ultimately causing 
accelerated loss of bone and increases the risk of osteoporotic fracture [48, 65]. 
 
The production of renal 1,25(OH)2D is stimulated via the actions of PTH [66]. 
Negative feedback from the serum levels of calcium and phosphate are also 
involved [48]. The classical targets of renal 1,25(OH)2D is the bone, kidneys and 
intestines [48]. This active form, 1,25(OH)2D, can be further catabolized in the 
kidneys. This only occurs when 1,25(OH)2D levels are sufficient. This step is 
carried out by the 24-hydroxylase enzyme (CYP24A) to form inactive 24,25-
dihydroxyvitamin D3 via a negative feedback loop (Figure 3). Active 
1,25(OH)2D3 induces expression of CYP24A, resulting in  hydroxylation of 
25(OH)D or 1,25(OH)2D at position 24, producing biologically inactive 
metabolites that can be excreted [61, 66]. 
   
1.2.3 Non-Classical Function 
Further research has revealed that the hormonal form 1,25(OH)2D has pleiotropic 
effects [67]. In addition to its classical endocrine action, both autocrine and 
paracrine pathways have been discovered [68]. Vitamin D is also involved in the 
regulation of cell growth, angiogenesis, apoptosis, and differentiation. 
Furthermore, as a chemopreventative agent in a number of cell types [67].  
 
It is now known that 25(OH)D can be utilised by a multitude of cell types to 
locally synthesise the hormonal form, 1,25(OH)2D [67]. The enzyme 25-
hydroxyvitamin D-1α-hydroxylase (CYP27B1), the vitamin D activating enzyme, 
is expressed by many peripheral tissues especially within the immune system [69, 
70]. The vitamin D receptor (VDR) has also been found in numerous extra-renal 
tissues and immune cells [71]. These vital components are found in most immune 
cells including, T cells [72], B cells [73], neutrophils [74], monocytes, 
macrophages [75] and dendritic cells [76]. Monocytes and macrophages have 
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been shown in vitro to upregulate both VDR and CYP27B1 (Figure 4), upon 
exposure to a bacterial lipopolysaccharide (LPS) or the microorganism 
Mycobacterium tuberculosis via TLR2/1 [77]. The potential therefore exists for 
the local production of 1,25(OH)2D.  
 
Bronchial epithelium and immune cells are capable of converting the circulating 
precursor 25(OH)D3 to local active 1,25(OH)2D3 [52]. It has been demonstrated 
that these epithelial cells of the respiratory tract are capable of having 
constitutively high levels of 1α-hydroxylase (CYP27B1) and low levels of the 
inactivating 24-hydroxylase. These elements therefore enable these cells to create 
a microenvironment with high active levels of vitamin D [52]. This allows 
localized synthesis at sites prone to inflammation [69]. 
 
 
Figure 4 1,25(OH)2D stimulates the innate immune system. TLR’s trigger the macrophage to 
increase VDR and CYP27B1 activation, ultimately causing synthesis of 1,25(OH)2D. 
1,25(OH)2D is then able to induce cathelicidin production, as published by Bikle 2009 [78]  
 
The nuclear VDR is a 1,25(OH)2D-activated transcription factor [61, 67]. Active 
1,25(OH)2D enters the target cells and binds to VDR in the cytoplasm, where it 
then enters the nucleus to form a heterodimer with the retinoid X receptor (RXR) 
[47, 79]. This complex can then bind to vitamin D response elements (VDRE’s) to 
regulate transcription of target genes [47, 61, 66]. VDRE’s are made up of PuG 
(G/T) TCA repeating motifs divided by three base pairs or reverse repeats 
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separated by six base pairs [66].   The fact that VDRE’s are highly conserved in 
humans and primates and not found in non-primate animals, suggests that is 
recent significant adaptation [80]. 1,25(OH)2D3 has been shown to regulate over 
900 genes in a microarray study [81]. 
 
The mechanisms for the regulation of non-renal 1,25(OH)2D is poorly understood, 
and is possibly under the control of local factors, for example, cytokines or 
growth factors [48, 82]. Local production is not regulated by PTH like renal forms, 
so 1,25(OH)2D concentration is dependent on its substrate 25(OH)D concentration 
[82].  
 
The importance of vitamin D on health has been increasingly acknowledged over 
the last decade. This is primarily due to the recognition of vitamin D as a 
modulator of numerous other biological responses, not just its traditional effects 
on skeletal health [67]. A considerable number of chronic and immune-mediated 
diseases can now be associated with vitamin D insufficiency [49]. The active form 
1,25(OH)2D is now known to have immunomodulatory effects due to its synthesis 
within epithelia and immune cells, and via its downstream effects on target genes.  
 
1.2.3.1 Immunomodulation of the Innate Immune System 
The innate immune system is an important non-specific first line of defence 
against infections [83]. Epithelial cells act as a protective physical barrier between 
the tissues and environment [83-85]. This barrier is especially important in the 
skin, gut, urinary and respiratory tract, where the innate immune system works to 
eliminate foreign organisms [83, 85]. Lungs and airways are constantly exposed 
to an array on inhaled pathogens and therefore require an effective innate immune 
system to ward against infection [84].  The active form, 1,25(OH)2D is potentially 
an important contribution to host defense of the lung [52].  
 
The hormonal form 1,25(OH)2D is now known to have potent immunomodulatory 
effects [61, 67]. The initial link between vitamin D and immunomodulatory 
effects came as a result of an association between vitamin D insufficiency and the 
occurrence of Mycobacterium tuberculosis [86]. The presence of vitamin D 
 18 
 
greatly increased killing of the mycobacterium, via upregulation of cathelicidin in 
macrophages upon exposure to a mycobacterial ligand (Figure 4)[77].  
  
These immunomodulatory effects arise via 1,25(OH)2D genomic actions. In vitro 
studies have shown that 1,25(OH)2D3 is involved in the direct regulation of 
antimicrobial peptides in numerous tissue types and cell lines [87, 88]. Both 
cathelicidin and β-defensin 2 (hBD-2) promoters contain VDRE’s [88].  
 
1.2.3.2 Antimicrobial Peptides 
Antimicrobial peptides (AMP’s) are a vital component of the vertebrate innate 
immune system and are regarded as an ‘evolutionary ancient weapon’ [89]. 
AMP’s are defined as cationic polypeptides consisting of less than 100 amino 
acids (generally 3-5kDa) that possess antimicrobial activity against bacteria (G
+
 
and G
-
), enveloped viruses and fungi, under physiological conditions [84, 90]. 
AMP’s are generally widespread and diverse in their nature. AMP’s have been 
isolated from many body secretions, as well as in numerous cell types. Certain 
parts of the amino acid sequence are highly conserved [84], particularly those 
involved in the translation, secretion and transport [89]. AMP’s are recently of 
interest as they show potential antimicrobial effects against antibiotic resistant 
bacterial strains [83], for example, Pseudomonas aeruginosa [88]. 
 
The broad spectrum antimicrobial function of these peptides comes from their 
ability to permeate and disrupt the membrane of target cells [83, 85, 89]. The 
outer bacterial membranes are generally negatively charged which provides an 
electrostatic attraction with the cationic peptide [83, 85]. AMP’s are also 
amphipathic in nature, possessing both hydrophilic and hydrophobic parts, which 
aids in membrane destabilization [83, 84]. Layering of AMP’s on the membrane 
leads to pore formation [91]. Eukaryotic cells are protected against AMP action 
due to the presence of cholesterol in the cell membrane [85]. Pathogen-associated 
molecular patterns (PAMP’s), for example, LPS, flagellin, or viral proteins, can 
stimulate pathogen recognition receptors (PRP’s) on cell membranes [92]. TLR’s 
are a class of PRP’s which when stimulated can then induce the CYP27B1 
enzyme (Figure 4) [93]. 
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There are numerous AMP families divided up based on their secondary protein 
structure. Defensins and cathelicidins are the two predominant AMP families in 
humans [84]. Defensins and cathelicidins have been found to have some 
synergistic actions [94, 95].  
 
The cathelicidins do not contain any cysteine residues allowing them to form a 
linear α-helical formation. The cathelicidin (CAMP) gene is located on 
chromosome 3 and is made up of four exons, only exon 4 is responsible for the 
antimicrobial properties [96]. The CAMP gene product is a pre-propeptide and 
becomes a propeptide once the signal sequence has been removed. The propeptide 
undergoes proteolytic processing (by proteinase 3 in neutrophils) to remove the 
‘cathelin-like domain’, to release the mature active peptide (LL-37) [97].  But 
there is only one cathelicidin found in humans, hCAP-18/LL-37 [84]. Cathelicidin 
is found in the secondary granules of both neutrophils and leucocytes [98].   
 
 Defensins are prevalent in humans where two major families exist, α- and β-
defensins [84]. Humans possess 6 α-defensins and 4 β-defensins genes located in 
a cluster on chromosome 8 [90]. The families are split based on differences in the 
pairing of the six cysteine residues that make up the three disulphide bridge [84, 
90]. These three disulphide bridges cause the peptide to fold into a β-sheet 
structure [83]. The β-defensins are typically larger in size than α-defensins.  
 
β-defensins are more widely distributed than α-defensins; the major synthesis of 
β-defensins is by epithelial cells. The expression of β-defensins 2-4 within 
epithelial cells has been revealed to be inducible [84], compared to human β-
defensin 1 which is continuously expressed [99]. hBD-2 can also be synthesized 
in monocytes, macrophages and dendritic cells [84]. The active defensin peptide 
is formed in a similar fashion to cathelicidin, with the signalling molecule and 
pro-region being removed to release the mature AMP (Figure 5) [100]. No single 
mechanisms of defensins antimicrobial properties has been identified but thought 
to be similar to cathelicidins mode of action.  
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Figure 5 Structural similarities of cathelicidin and defensin precursors, as published by Kolls 
et al., 2008 [100] 
All of the cathelicidins and defensins have numerous other immune regulatory 
functions in addition to their antimicrobial activity (Figure 6), both can act as 
chemoattractants [84, 94]. In addition to its antimicrobial properties as part of the 
innate immune system, LL-37 also acts as a signalling molecule helping to 
regulate the adaptive immune system [101]. Cathelicidin can act as a 
chemoattractant to recruit immune cells to sites of infection and also mediates 
proinflammatory actions [96, 102].  
 
 
Figure 6 All known biological functions of mammalian antimicrobial peptides that function 
in innate immune system, as published by Gallo & Nizet, 2003 [94] 
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Importantly, both defensins and cathelicidins are found in airway and lung 
epithelium, as well as lung secretions [84, 103]. Their expression is generally 
triggered mainly by exposure to microbial products, for example, LPS via toll-like 
receptors [88], but also to cytokines and growth factors [84]. 1,25(OH)2D3 is now 
recognised as a direct regulator of AMP expression. 1,25(OH)2D3 alone causes 
strong induction of CAMP expression but modest effect on hBD2 expression [88]. 
The genes of both cathelicidin and hBD-2 contain VDRE’s in their promoters; 
507bp and 1231bp upstream of start codon respectively (Figure 7) [88]. The 
VDRE in the CAMP gene is embedded in an Alu repeat transposable element 
(primate specific) [80].  
 
 
Figure 7 The location of the camp and hBD-2 gene’s VDRE’s in the promoter region, as 
published by Wang et al., 2004 [88] 
 
1.2.3.3 Vitamin D Regulation of Antimicrobial Peptides Studies 
Multiple regulators have been identified in the expression of LL-37 and hBD-2. 
One of which is the hormonally active form of vitamin D, 1,25(OH)2D3, which 
has been shown to regulate the expression of hBD-2 and LL-37 in a variety of cell 
types [87, 88]. Altered expression of AMP’s occurs during inflammation and 
infection. Increased expression is commonly seen in individuals with 
inflammatory or infectious diseases [84]. 
 
Wang et al., 2004 study tested the expression of the CAMP and hBD-2 genes in 
vitro in specific human cell types. Both CAMP and hBD-2 genes contain VDRE’s 
in their promoter region. The treatment of these cell types with 1,25(OH)2D3 
caused the induction of LL-37 expression, observed by the mRNA upregulation in 
all cell types tested.  These cells included keratinocytes, neutrophils, monocytes, 
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squamous carcinoma cells (SCC25), lung adenocarcinoma (Calu-3), and 
myelomonocytic cells (U937).  The induced LL-37 was then shown to have 
antimicrobial properties against Pseudomonas aeruginosa. The hBD-2 expression 
though was only enhanced in certain epithelial cell types, SCC25 and 
keratinocytes. This is consistent with hBD-2 only being expressed in epithelial 
cells [88].  
 
Other in vitro research further supports the upregulation of CAMP expression by 
1,25(OH)2D3 in other human cell lines and primary cultures including, urogenital 
cells, epithelial cells, neutrophils, lung [88], bronchial [104], colon, macrophages, 
keratinocytes and myeloid cell lines [87].  
 
Various association studies have revealed contrasting results for effects of vitamin 
D on antimicrobial concentrations in vivo. Jeng et al., 2009 research found a weak, 
but statistically significant positive association, between serum 25(OH)D and LL-
37 in critically ill patients, with and without sepsis [105]. Another study has 
shown that serum hCAP18 is associated with increased mortality from infection in 
those with end-stage renal disease. No association was found between 25(OH)D 
and hCAP18. But interestingly a borderline association (p=0.053) between serum 
1,25(OH)2D and hCAP18  was found [106].   
 
Respiratory studies have looked at the levels of vitamin D, cathelicidin and hBD-2 
in community acquired pneumonia. Severe VDD (<30nmol/L) was associated 
with the increased 30-day mortality rate. But no correlation was found with 
25(OH)D serum levels and antimicrobial levels [107]. Similarly, in a recent 
bronchiectasis study it was hypothesized that LL-37 levels in the airways would 
decrease in vitamin D deficient individuals. The results showed the opposite, with 
the highest LL-37 levels being found in the vitamin D deficient group. This 
suggests that vitamin D effects in vivo have little effect on LL-37 level [43]. 
Currently limited evidence supports the action of 1,25(OH)2D on antimicrobial 
levels in vivo. 
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1.3 Vitamin D Deficiency 
The occurrence of suboptimal vitamin D levels is widespread, with an estimated 
one billion individuals globally being estimated as vitamin D deficient [43]. The 
mean concentration of 25(OH)D in New Zealand adults (over 15 years) is 
50nmol/L (n=2,946) [50]; identical mean to the UK National Diet and Nutrition 
Survey (2000-2001) by Ruston et al., 2004 [108]. In total 3% of the New Zealand 
sample population is regarded as deficient (<17.5nmol/L) and 48% insufficient 
(<50nmol/L); 84% (<80nmol/L) were insufficient based on different cut-offs 
points used [109] for vitamin D insufficiency [50]. Lower vitamin D levels were 
reported in Maori (mean=42nmol/L) and Pacific (mean-37nmol/L) [50]. UK 
nationwide study reported that 50% adults vitamin D insufficient and 16% 
severely deficient [108]. Higher rates have been reported in Scotland [110].  
 
Risk factors of VDD include latitude, lack of sunlight, sunscreen use, poor diet, 
obesity, premature birth, gender, ethnicity, and age [48, 49]. These risk factors all 
prevent UVB radiation from reaching the skin. UVB radiation (300-325nm) is 
required for the thermal isomerization of precursor 7-dehydrocholesterol which 
varies due to latitude and seasonality [111]. The amount of UVB photons getting 
to earth relies on the sun’s zenith angle [49]. New Zealand is located at a high 
latitude (35-47°C) meaning that radiation intensity is inadequate for long periods 
of the year [50]. In New Zealand the most significant determinants are ethnicity 
and season [112].  Darker skin has higher concentrations of melanin, which is 
known to decrease the synthesis of vitamin D from its precursor 7-
dehydrocholesterol [65, 113]. Age is also an identified risk factor as there is a 
reduced concentration of the vitamin D precursor, 7-dehydrocholesterol, within 
the skin [65]. 
 
1.3.1 Measuring Vitamin D Status 
Serum 25(OH)D levels are the best short-term measure of vitamin D status. 
25(OH)D is the primary form of circulating vitamin D metabolite [60, 114], with 
a half-life of approximately 3 weeks [115]. This makes it the most accurate 
metabolite for measuring total vitamin D status [51]. The production of 25(OH)D 
is not tightly regulated like the hormonal form of vitamin D (1,25(OH)2D), 
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therefore only dependent on its substrates concentration [82]. 1,25(OH)2D is 
typically not used in the assessment of vitamin D status as it has a relatively short 
half-life (4 hours) and is tightly regulated by calcium homeostasis [60].  
 
Determining vitamin D status is complex due to the number of vitamin D 
metabolites, particularly the two forms vitamin D2 and vitamin D3 [60], as well as 
the free vitamin D levels [60]. Approximately 99% of vitamin D metabolites are  
bound within the blood [116], this may affect their transportation into airways 
[117]. DBP is the predominant serum carrier of vitamin D and its metabolites [54, 
60]. Single nucleotide polymorphisms in genes involved in vitamin D transport 
and metabolism may be a contributing factor in VDD, for example, DBP and 
VDR. Polymorphisms may be affecting the bioavailability of circulating vitamin 
D [118].  
 
Determining vitamin D status is difficult as there is no unified consensus on the 
required or optimal serum concentration of 25(OH)D for optimal health [47, 49, 
112]. A number of studies suggest a level of less than 50nmol/L (<20ng/mL) of 
25(OH)D for VDD, insufficient level of 50-75nmol/L (<20-30ng/mL) [49, 112, 
119] and sufficient levels of 75-80nmol/L (30-32ng/mL) [120-122]. Vitamin D 
intoxication is very rare and occurs at 25(OH)D levels above 375nmol/L 
(150ng/mL) [49].                     
 
To further complicate matters, suggestions have been made the levels required for 
bone health may vary from that required for its other functions. There is an 
inverse relationship between 25(OH)D concentrations and levels of circulating 
PTH until reaches 30ng/mL where PTH plateaus [66, 121, 122]. The current 
status quo level of 50nmol/L serum level of 25(OH)D may not be enough for the 
prevention of other diseases. The serum 25(OH)D level may in fact need to be 
higher, for example, 75-80nmol/L [123] or 100-150nmol/L [93]. The evidence to 
support this is currently limited and further research is needed. The levels required 
for bone health may vary from that required for its other functions.  
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1.3.2 Treatment of Vitamin D Deficiency 
Supplementation for VDD is currently being reinvestigated. Current 
supplementation guidelines (Food and Nutrition Board) suggest 200 IU/day for 
those aged under 50 years; 400 IU/day for those between 50-70 years; and 600 
IU/day for those over 70 years [65]. Further research is needed to determine the 
best dosing strategy for the treatment of VDD [124].  
 
Often no observed change in serum 25(OH)D is seen after a vitamin D dosing 
regimen [124]. Emerging evidence is indicating that cholecalciferol (vitamin D3) 
may be a more efficacious form [124, 125]. A recent study has shown that the 
potency of vitamin D2 is only one-third of the potency of vitamin D3, achieved by 
mapping the time-course of 25(OH)D3 after a single dose [124]. Potentially this is 
due to DBP having a higher affinity for vitamin D3 leading to it having a longer 
circulating half-life [124]. More research in needed to come up with a 
standardized way of measuring and dosing VDD. 
 
1.4 Vitamin D Deficiency and Chronic Disease 
The hormonal form 1,25(OH)2D due to its pleiotropic actions has been associated 
with decreased risk of many chronic diseases [49]. The actions of vitamin D have 
been implicated with various autoimmune, cardiovascular, respiratory [43], 
metabolic and infectious diseases [49]. Also, associated with certain cancers [49, 
126-128], diabetes [129], muscle weakness, hypertension and neurological 
conditions (eg. multiple sclerosis [130]) [49].  
 
Vitamin D was unknowingly used to treat tuberculosis, where it was found to be 
the active component of Cod Liver Oil which was a commonly used treatment. 
UV light was also commonly used to treat forms of TB during the mid-1900. 
VDD is a risk factor for tuberculosis [131]. One study has shown that exposure of 
Mycobacterium tuberculosis to TLR2/1 caused increased expression of VDR and 
CYP27B1 in monocytes [77]. 1,25(OH)2D treatment resulted in killing of 
Mycobacterium tuberculosis in cultured human macrophages [132].  
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VDD has also been linked to an enhanced risk of respiratory infections [43, 133]. 
A VDD mouse model shows changes in lung structure and a decreased lung 
function [134]. Associations have been found between low levels of vitamin D 
and the occurrence of respiratory tract infections in both Finnish [135] and 
American populations [136]. Low vitamin D levels have been found in patients 
with COPD and found to correlate with COPD severity [133]. Another study has 
looked at the vitamin D levels and community-acquired pneumonia. Severe VDD 
(<30nmol/L) was associated with the increased 30-day mortality rate in these 
patients [107]. 
 
1.4.1 Vitamin D Deficiency and Bronchiectasis 
Chalmers et al., 2013 paper provides the first study providing data on the 
association of VDD in bronchiectasis and disease severity [43]. VDD has been 
previously associated with a risk of respiratory infections; now including 
bronchiectasis. This research measured the concentration of 25(OH)D in 402 
stable non-cystic fibrosis bronchiectasis patients. A total of 50% deemed vitamin 
D deficient (<25nmol/L), 43% insufficient (25-74nmol/L) and 7% sufficient 
(>75nmol/L), compared to 12% deficient in control [43].  
 
VDD is found to be associated with several markers of bronchiectasis disease 
severity, particularly chronic bacterial colonisation. A total of 21.4% of vitamin D 
deficient bronchiectasis patients were chronically colonised by Pseudomonas 
aeruginosa, compared to only 10.4% of insufficient patients and 3.6% of 
sufficient patients. Those classed as vitamin D deficient exhibited lower %FEV1, 
accelerated decline in lung function, higher frequency of exacerbations, more 
severe exacerbations, worse health-related quality of life (SGRQ and LCQ) and 
higher levels of sputum inflammatory markers [43].   
 
More evidence is needed to determine exact causality. But these results suggest 
that a randomised controlled trial of vitamin D replacement therapy may be 
beneficial to determine if any changes occur in clinical outcomes [43]. Important 
to note that VDD most often results from lack of sunlight and that having a 
respiratory condition often leads to reduced outdoor activities [43, 49, 108, 133].  
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1.5 Inflammatory Markers 
Inflammatory markers are biomarkers in the blood that indicate the amount of 
inflammation occurring during an infection. This can then potentially be used to 
guide antibiotic therapy and aid in prognosis [137, 138]. Bronchiectasis patients 
are susceptible to reoccurring lower respiratory tract infections, which produce an 
inflammatory response [5]. 
 
There are indications that stable patients with non-cystic fibrosis bronchiectasis 
actually have consistently elevated systemic markers of inflammation, including  
C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) [139]. Due to 
chronic infection, bronchiectasis patients continue to have active local and 
systemic inflammation even during stable phase [137, 140].  Currently no specific 
inflammatory marker suitable for bronchiectasis has been found [138]. 
 
Procalcitonin (PCT) is a relatively new, yet still controversial, marker of 
inflammation that proved useful in the treatment of some conditions [141-143]. 
PCT is the precursor peptide of calcitonin (a hormone), that is increased in 
response to bacterial infections. Is typically secreted by the body’s parenchymal 
cells and is produced in the C cells of the thyroid gland [144]. In response to a 
period of inflammation should see an elevated serum level. Normally PCT levels 
are very low (<0.05ng/mL), as PCT is not constitutively released into the blood, 
and only mildly elevated in viral infections (up to 2 ng/mL) [145]. But in severe 
bacterial infections serum PCT can reach over 700ng/mL [145].  
 
A number of studies have indicated the usefulness of PCT in separating infections 
that are viral or bacterial [146]. CRP is regarded as a nonspecific inflammatory 
marker of systemic inflammation. PCT is considered to be potentially more 
sensitive and specific, than the more commonly used CRP in defining bacterial 
infections over systemic infections [147]. PCT also peaks sooner after infection (8 
hours) compared to traditional CRP (36 hours) [147].  
 
PCT has proved useful in reducing the amount of antibiotics administrated but 
with no change in clinical outcome [141-143]. Reduction in antibiotic use shown 
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in sepsis (down 23%) [143], in LTRI, COPD, community-acquired pneumonia 
(reduction of 55% antibiotic days) [148, 149] and in COPD [142]. Using PCT 
may provide additional prognostic information for patients that are at high risk, as 
indicated in community-acquired pneumonia [150]. These studies are based on 
specific cut-off points: 0.1ug/L indicates no bacterial infection/no antibiotics 
required, 0.1-0.25ug/L bacterial infection unlikely/only antibiotics if high risk 
patient, 0.25-0.5ug/L indicates possible bacteria/requires antibiotics and >0.5ug/L 
strong bacterial infection/antibiotics needed [148, 149]. 
 
To date, Loebinger et al., 2008 study is the only one on PCT in bronchiectasis 
patients. PCT may be able to guide in bronchiectasis exacerbation treatment, 
enabling the length of the antibiotic course to be personalized [137, 138]. This 
investigation found that patients admitted with an infective exacerbation had quite 
low or negative PCT levels (0.055ug/L) [138], similar to another COPD study 
(0.096ug/L) [142]. Pneumonia typically has higher concentrations (0.5ug/L) [150]. 
This may be due to the fact that in COPD and bronchiectasis inflammation is 
more localized [138]. No published research to date has investigated the levels of 
PCT in sputum. 
 
1.6 Study Design 
This research is a sub-component of a multi-centre clinical trial investigating the 
usefulness of Tiotropium in the treatment of non-cystic fibrosis bronchiectasis. 
Tiotropium is a novel inhaled anticholinergic drug that only requires once a day 
dosage. The prolonged bronchodilatory effect of Tiotropium comes from its 
prolonged antagonism of muscarinic receptors. The use of Tiotropium has been 
linked to improvements in airflow in COPD [151, 152].  
 
The clinical trial was run as a double-blind crossover study. For each half of the 
54 weeks patients would receive either the drug or placebo; with serum and 
sputum samples being collected at Weeks 1, 26, 30 and 54. These samples 
allowed an investigation into the role of vitamin D, cathelicidin, hBD-2 and PCT 
in stable bronchiectasis patients. Using enzyme-linked immunosorbent assay 
(ELISA). These concentrations will be analysed for any association using 
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predetermined cut-off points or tertiles, and Spearman’s non-parametric 
correlations. 
 
1.6.1 Vitamin D Analytes 
Vitamin D status is determined by measuring serum 25(OH)D levels. 25(OH)D is 
the predominant circulating vitamin D metabolite that provides the best measure 
of vitamin D status. The cut-off points that will be used are: <30nmol/L severe 
VDD, <50nmol/L VDD, 50-75nmol/L insufficient (<20-30ng/mL) [49, 112, 119] 
and >75nmol/L sufficient [120-122].  
 
Vitamin D is now known to directly regulate specific target genes. In vitro studies 
have shown the ability of 1,25(OH)2D3 to directly regulate the expression of 
various AMP’s, including cathelicidin. But previous studies of community 
acquired pneumonia, have failed to show any correlation between vitamin D 
concentrations with the AMP’s (cathelicidin and hBD-2) [107]. Potentially the 
reason for this lack of association could be due to serum levels not accurately 
representing localized tissue levels. In fact there may be an unequal distribution of 
vitamin D, making the analysis of vitamin D metabolites in sputum important. 
Very little is known about the concentrations of vitamin D metabolites in tissues 
and along mucosal surfaces. In human bronchoalveolar fluid (BAL), levels of 
vitamin D metabolites were typically very low [117].  
   
1,25(OH)2D is typically not used in the assessment of vitamin D status, as has a 
relatively short half-life (4 hours) compared to 25(OH)D (3 weeks). There is a 
limited number of studies that have measured 1,25(OH)2D concentration in serum. 
There is no consensus on normal 1,25(OH)2D but renal 1,25(OH)2D is generally 
tightly regulated and not severely affected by fluctuating 25(OH)D serum levels. 
One Danish study reports an average 1,25(OH)2D level of 29.0pg/mL (+/-
9.5pg/mL) [153]. This is supported by an older study which revealed an average 
of 23.6pg/mL (+/-1.3pg/mL) in the control group [154]. 
 
But very little is understood about the local activation of vitamin D metabolites in 
these extra-renal tissues or mucosal surfaces. Or what their relationship is to the 
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circulating levels of cathelicidin and hBD-2. The effect of 1,25(OH)2D on 
expression of cathelicidin and hBD-2 has only been shown so far in vitro not in 
vivo [87, 88, 117]. Measuring the levels of both 25(OH)D3 and 1,25(OH)2D3 in 
serum and sputum may reveal novel findings in their association with AMP levels 
in vivo. Tertiles will be used in the assessment of 1,25(OH)2D3, cathelicidin and 
hBD-2 concentrations, as no current consensus levels are available. 
 
1.6.2 Procalcitonin 
PCT levels will be split into none, low, moderate or high. The low value will be 
those below 0.1ug/L (100pg/mL) which is commonly reported in normal healthy 
individuals and is associated with no bacterial infections. High PCT levels will be 
those above 0.5ug/L which indicates the presence of a strong bacterial infection 
[148, 149]. Moderate will be those that fall in between these values.  
 
No published research to date has investigated the levels of PCT in sputum. It is 
estimated that PCT levels will be greater in sputum compared to serum levels. 
This is purely due to sputum being located at a site with a high density of bacteria 
and the presence of inflammatory cells. Unpublished data supports elevated PCT 
levels being present in sputum (2ng/mL) against serum (<0.5ng/mL) in 
bronchiectasis patients with acute exacerbations (Wong et al., 2011).
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1.7 Research Objectives 
The main objective of the study was to analyse the levels of vitamin D metabolites 
and antimicrobial peptides in stable bronchiectasis patients. The identification of 
any associations may provide an insight on the mechanisms involved in the 
development and progression of non-cystic fibrosis bronchiectasis. This may 
ultimately lead to improvement of the prevention and management of non-cystic 
fibrosis bronchiectasis. 
 
1.7.1 Aims 
1) The primary aim of this research was to determine if differences exist 
between systemic (serum) and local (sputum) tissue concentrations of 
vitamin D metabolites, cathelicidin, β-defensin 2 and procalcitonin.  
 
2) The secondary aim was to assess the serum vitamin D status in clinically 
stable bronchiectasis patients. 
 
3) Lastly, to determine if there is an association between vitamin D status and 
the levels of antimicrobial peptides, cathelicidin and β-defensin 2 in 
individuals with bronchiectasis. 
 
1.7.2 Hypotheses 
Hypothesis One 
There will be differences between the localised and systemic concentrations of 
vitamin D, cathelicidin, β-defensin 2 and procalcitonin in non-cystic fibrosis 
bronchiectasis patients. A null hypothesis proposes that there will be no difference 
between localised and systemic levels of vitamin D, cathelicidin, β-defensin 2 and 
procalcitonin in bronchiectasis.  
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Hypothesis Two 
Vitamin D deficiency will be prevalent in stable non-cystic fibrosis bronchiectasis 
patients. A null hypothesis proposes that vitamin D deficiency will not be 
associated with the occurrence of bronchiectasis. 
Hypothesis Three 
Non-cystic fibrosis bronchiectasis individuals with lower vitamin D levels will 
correspondingly have decreased levels of antimicrobial peptides, cathelicidin and 
β-defensin 2. A null hypothesis proposes that there will be no association between 
vitamin D concentration and antimicrobial peptide concentrations. 
 
 
 33 
 
Chapter Two: Methodologies 
 
2.1 Sample Collection 
This research was a subcomponent of a trial investigating the usefulness of 
Tiotropium in the treatment of bronchiectasis. Patients were being recruited from 
Waikato Hospital, Middlemore Hospital and Auckland Hospital. Ethical approval 
was obtained from the Northern Y Regional Ethics Committee (NTY/11/10/104).  
Participants selected for the trial were recruited from Middlemore and Auckland 
Hospitals. Written consent was obtained from each participant and their medical 
details were recorded. 
 
The clinical trial was a double-blind crossover study run over a period of 54 
weeks. These 54 weeks were divided up into two study periods. In one study 
period patients would receive Tiotropium and in the other a placebo based on their 
randomisation code. Whole blood and sputum samples were obtained at the initial 
visit (Visit One), 26 weeks (Visit Five), 30 weeks (Visit Six) and 54 weeks (Visit 
Nine). The visit’s one and six serve as controls for their respective study period. 
 
Peripheral whole blood and sputum was obtained at specific visits by a medical 
doctor. These were then processed at the hospital lab (2.2) to obtain the serum and 
sputum supernatant. These samples were then transported to the Molecular 
Genetics Laboratory at The University of Waikato (C.2.03) and stored at -80°C 
until required for ELISA analysis. 
 
2.2 Sample Preparation 
After blood and sputum samples have been collected both need to be processed to 
a more usable form for ELISA analysis. Serum and sputum supernatant is 
required for the measurement of PCT, cathelicidin, β-defensin 2, 25(OH)D3 and 
1,25(OH)2D3. Sputum supernatant is a more workable solution than pure sputum. 
All serum and sputum samples were stored at -80°C and then transferred to a 
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different lab to undergo analysis of PCT, β-defensin 2, cathelicidin, 25(OH)D3 
and 1,25(OH)2D3. 
 
2.2.1 Serum Processing 
The following procedure was undertaken at Middlemore Hospital and Auckland 
Hospital following collection of the patient’s whole blood samples. 
1. Collect whole blood sample. 
2. Leave the blood to clot by leaving undisturbed at room temperature for 
approximately 15-30 minutes. 
3. Centrifuge at 2500rpm for ten minutes in a refrigerated centrifuge. 
4. The resultant supernatant is the serum. Remove carefully using a Pasteur 
pipette. 
5. Samples stored in 1mL aliquots and stored at -80°C until analysed. 
6. Avid repeated freeze-thaw cycles. 
 
2.2.2 Sputum Processing 
The following procedure was undertaken at Middlemore Hospital and Auckland 
Hospital following collection of the patient’s sputum samples. 
1. Weigh the sample and add twice the volume of 10% Sputolysin. (Note: 
results in a 1:3 dilution of sputum; one part sputum and two parts 
sputolysin). 
2. Mix with syringe and cannula, place cap on falcon tube and use parafilm 
to seal. 
3. Put into shaking water bath for 30 minutes at 37°C (test if sample 
homogenous). 
4. Mix gently and aspirate into a 10mL syringe using cannula. 
5. Filter using 50μm filter fabric inner and at a rate of 1 drop per second. 
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6. Gently mix and pipette 100μL of sample into Eppendorf tube. Add equal 
volume of Trypan blue. 
7. Using Haemocytometer perform a total cell count. 
8. Remaining sputum split into 1.6mL Eppendorf tubes and stored at -80°C; 
samples marked if screen-failed.  
 
2.3 ELISA Kits 
Enzyme-linked immunoassay is commonly used to perform quantification of 
specified analytes. ELISA was used to determine the concentrations of PCT, 
cathelicidin, hBD-2, 25(OH)D3 and 1,25(OH)2D3 in both serum and sputum. Each 
ELISA assay was carried out in duplicate and using internal standards for 
producing a standard curve, allowing the quantification of analyte concentration. 
 
2.3.1 USCN Life Science ELISA Kit 
Commercially available sandwich enzyme immunoassay kits (USCN Life Science 
Inc., Wuhan, China) were used for independent in vitro measurement of PCT, 
cathelicidin and hBD-2. These kits were capable of measuring these analytes in 
human serum, plasma and other biological fluids. ELISA’s were run according to 
manufacturer’s protocol. 
 
2.3.1.1 Procalcitonin Reagent and Sample Preparation 
2.3.1.1.1 Sample Dilution 
Samples need to be brought to room temperature before being used for ELISA. 
Both serum and sputum samples required no dilution for ELISA quantification. 
(Note: sputum processing produced a 1:3 sputum dilution) 
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2.3.1.1.2 Standard Preparation 
Reconstitute the standard with 1.0mL Standard Diluent (room temperature) and 
mix gently. From the stock solution (4,000pg/mL) produce the following double 
dilution series: 
 
Figure 8 Standard double dilution series for USCN Life Sciences human PCT ELISA 
Standard diluent serves as the blank for the standard dilutions.  
2.3.1.1.3 Reagent Preparation 
All reagents must be prepared fresh and utilised at room temperature. 
Assay Diluent A /Assay Diluent B Working Solution: Dilute 6mL of Assay 
Diluent A or B Concentrate (2x) with 6mL de-ionized water, to produce a total of 
12mL. 
Detection Reagent A/Detection Reagent B: Dilute to a 1:100 working 
concentration with Assay Diluent A/Assay Diluent B working solution. 
 
2.3.1.2 Cathelicidin Reagent and Sample Preparation 
2.3.1.2.1 Sample Dilution  
Samples need to be brought to room temperature before used for ELISA. 
Optimal dilution factor for ELISA assay was determined. 1:500 dilution for serum 
samples with 0.02mol/L PBS (pH=7-7.2). 1:5000 dilution for sputum samples 
with 0.02mol/L PBS (pH=7-7.2). (Note: sputum samples already diluted 1:3 so 
total dilution is 1:15000) 
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2.3.1.2.2 Standard Preparation 
Reconstitute the standard with 1.0mL Standard Diluent (room temperature) and 
mix gently. From the stock solution (8,000pg/mL) produce the following double 
dilution series: 
 
Figure 9 Standard double dilution series for USCN Life Sciences human cathelicidin 
antimicrobial peptide ELISA 
Standard diluent serves as the blank for the standard dilutions.  
2.3.1.2.3 Reagent Preparation 
All reagents must be prepared fresh and utilised at room temperature. 
Follow the procedure as above for PCT for making Detection Reagent A and B 
working solution. 
 
2.3.1.3 β-defensin 2 Reagent and Sample Preparation 
2.3.1.3.1 Sample Dilution 
Samples need to be brought to room temperature before used for ELISA. 
Both serum and sputum samples required no dilution for ELISA quantification. 
(Note: sputum processing produced a 1:3 sputum dilution) 
2.3.1.3.2 Standard Preparation 
Reconstitute the standard with 1.0ml Standard Diluent (room temperature) and 
mix gently. From the stock solution (6,000pg/mL) produce the following double 
dilution series: 
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Figure 10 Standard double dilution series for USCN Life Sciences hBD-2 antimicrobial 
peptide ELISA 
Standard diluent serves as the blank for the standard dilutions.  
2.3.1.3.3 Reagent Preparation 
All reagents must be prepared fresh and utilised at room temperature. 
 
Follow the procedure as above for PCT for making Detection Reagent 
A/Detection Reagent B working solution. 
 
Quality Control: Reconstitute the vial with 150μL of standard diluent, mix gently 
and let stand for 10 minutes. Add 100μL to a well. Expected concentration is 
540.1pg/mL. (Note: quality control was only provided for the newest kit)  
 
2.3.1.4 General Assay Procedure for Procalcitonin, Cathelicidin and β-
defensin 2 
1. Remove required numbers of strips from 96-well plate. Add 100μL of 
each standard dilution (7 wells), blank (1 well), quality control (if 
provided) and samples into predetermined wells. Cover with plate sealer 
and incubate for 2 hours at 37°C. 
2. Aspirate wells, do not wash. 
3. To each well add 100μL of Detection Reagent A working solution. Cover 
with plate sealer and incubate for 1 hour at 37°C. 
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4. Aspirate solution and wash three times using 350μL volume of Wash 
Buffer (1X PBS, 0.1% Tween 20) per well on automated plate washer 
(Thermofisher Scientific
TM
 Wellwash Versa
TM 
Microplate Washer). 
5. To each well add 100μL of Detection Reagent B working solution. Cover 
with plate sealer and incubate for 30 minutes at 37°C. 
6. Repeat wash step but for a total of five times. 
7. Add 90uL of TMB substrate solution to each well. Use new plate sealer 
and incubate for 15-25 minutes. Wells should turn blue. 
8. After incubation add 50μL of Stop solution and tap plate gently on side to 
mix. Liquid should turn yellow. 
9. Immediately measure optical density (OD) at 450nm using microplate 
reader (Thermofisher Scientific
TM
 Multiskan Go
TM  
Microplate 
Spectrophotometer). 
 
2.3.2 Hycult Biotech Human LL-37 ELISA Kit 
This commercially available kit is a solid-phase enzyme-linked immunosorbent 
assay based on the sandwich principle for the determination of human LL-37. 
Samples are incubated in wells that are coated with antibodies specific for human 
LL-37. The added biotinylated tracer antibody will bind to the captured LL-37. 
The Streptavidin-peroxidase conjugate will bind to the tracer antibody. The S-P 
conjugate will react with the tetramethylbenzidine (TMB) substrate to produce a 
blue colour. The enzymatic action is then stopped by the addition of oxalic acid to 
produce a yellow colour. LL-37 is the antibacterial C-terminus (37 amino acids) 
of hCAP 18. ELISA kit was run according to manufacturer’s protocol.  
2.3.2.1 Sample Dilution 
All serum samples required a 1:20 dilution with supplied wash/dilution buffer. 
Sputum samples required a 1:200 dilution with supplied wash/dilution buffer. 
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2.3.2.2 Reagent Preparation 
All reagents are to be brought to room temperature prior to use. All required 
reagents are to be prepared fresh. 
 
Wash/Dilution Buffer:  
1. Determined the required volume for the amount of dilutions being done.  
2. Mix 1 part 20X concentrated wash/dilution buffer A with 9 parts de-
ionized water. 
3. Mix 1 part 40X concentrated wash/dilution buffer B with 19 parts de-
ionized water. 
4. Combine both solutions equally and mix well. 
Tracer Solution:  
1. Reconstitute the tracer with 1mL of de-ionized water. 
2. Determine required tracer volume for number of test wells. 
3. Dilution requires 1 part of reconstituted tracer and 11 parts of 
wash/dilution buffer. Mix thoroughly. 
Streptavidin-peroxidase Solution:  
1. Reconstitute the streptavidin-peroxidase with 1mL of de-ionized water. 
2. Determine required streptavidin-peroxidase volume for number of test 
wells. 
3. Dilution requires 1 part of reconstituted streptavidin-peroxidase with 23 
parts of wash/dilution buffer. Mix thoroughly. 
2.3.2.3 Standard Preparation 
Reconstitute the standard with 0.5mL de-ionized water. Prepare the standard serial 
dilution using wash/dilution buffer from the stock standard (242ng/mL) as follows: 
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Figure 11 Standard dilution series for Hycult LL-37 ELISA 
From the Certificate of Analysis (CoA): the amount of wash/dilution buffer to be 
used in tube 1 is 0.213mL. 
 
2.3.2.4 ELISA Protocol 
All reagents are to be brought to room temperature prior to use. It is important 
that the same pipetting order is followed. 
1. Remove required number of microwell strips. 
2. In duplicate add 100μL of standard, sample, or controls to predetermined 
wells. 
3. Cover with plate sealer and incubate for 1 hour at room temperature. 
4. Wash plate four times using automated plate washer (Thermofisher 
Scientific
TM
 Wellwash Versa
TM 
Microplate Washer) (300ul/well) with 
Wash Buffer (1x PBS, 0.1% Tween 20). 
5. Add 100μL of diluted tracer to each well, cover and incubate for 1 hour at 
room temperature. 
6. Repeat wash procedure (Step 4). 
7. Add 100μL of diluted streptavidin-peroxidase to each well, cover and 
incubate for one hour at room temperature. 
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8. Repeat wash procedure (Step 4). 
9. Add 100μL of TMB substrate to each well, cover tray with tin foil (light 
sensitive) and incubate for 30 minutes at room temperature. 
10. Add 100μL of stop solution. Gently swirl the plate to mix and to remove 
any air bubbles. 
11. Within 30 minutes read the plate using the microplate reader 
(Thermofisher Scientific
TM
 Multiskan Go
TM  
Microplate 
Spectrophotometer) at 450nm. 
 
2.3.3 Vitamin D Cusabio ELISA Kits 
Two separate competitive inhibition enzyme immunoassay kits for the 
quantification of 25(OH)D3 and 1,25(OH)2D3 concentrations in human serum. 
The plates come pre-coated with the specific antibody. Samples are added to the 
wells with Horseradish Peroxidase (HRP) conjugated 25(OH)D3 (or 1,25(OH)2D3) 
Hapten. There is then a competitive inhibition reaction between HRP-conjugated 
25(OH)D3 (or 1,25(OH)2D3) Hapten and the 25(OH)D3 (or 1,25(OH)2D3) present 
in the samples. Substrate solution is then added and the colour reaction develops 
inversely to the actual amount of 25(OH)D3 (or 1,25(OH)2D3) present in the 
sample. This colour reaction is then stopped and absorbency read. Concentrations 
determined by producing a standard curve using four-parameter logistic curve fit. 
ELISA kits were run according to manufacturer’s protocol. 
 
2.3.3.1 Human 25-hydroxyvitamin D3 Reagent and Sample 
Preparation 
2.3.3.1.1 Sample Dilution 
The optimal dilution for serum samples was 1:30, diluted using the provided 
Sample Diluent. No dilution is required for the sputum dilution. (Note: sputum is 
already diluted 1:3 due to the sputum processing procedure) 
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2.3.3.1.2 Standard Preparation 
Reconstitute the vial with 0.5ml de-ionized water, mix thoroughly and let sit for 
15 minutes. Dilute the stock solution (4,000μg/L) 40-fold to produce Standard 4 
(100μg/L). Then dilute Standard 4 as follows to produce the required standard 
dilutions: 
Table 2 Required standard dilution series for 25(OH)D3 ELISA 
Tube S4 S3 S2 S1 S0 
Conc. (μg/L) 100 80 40 20 0 
S4 (μL) 200 160 80 40 0 
Samples 
Diluent (μL) 
0 40 120 160 200 
2.3.3.1.3 Reagent Preparation    
High Value Control (HVC): Reconstitute with 0.5mL of de-ionized water. Mix 
thoroughly and then allow it to sit for 15 minutes. Dilute reconstituted high value 
control 1:40 with standard diluent. 
Middle Value Control (MVC): Reconstitute with 0.5mL of de-ionized water. Mix 
thoroughly and then allow it to sit for 15 minutes. Dilute reconstituted middle 
value control 1:40 with standard diluent. 
 
2.3.3.2 Human 1,25-dihydroxyvitamin D3 Reagent and Sample 
Preparation 
2.3.3.2.1 Sample Dilution  
The optimal dilution for serum samples was 1:10, diluted using the provided 
Sample Diluent. No dilution is required for the sputum dilution. (Note: sputum is 
already diluted 1:3 due to the sputum processing procedure) 
2.3.3.2.2 Standard Preparation 
Reconstitute the vial with 0.5mL de-ionized water, mix thoroughly and let sit for 
15 minutes. Dilute the stock solution (200,000fmol/L) 40-fold to produce 
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Standard 4 (5000 fmol/L). Then dilute standard 4 as follows to produce required 
standard dilutions: 
Table 3 Required standard dilution series for 1,25(OH)2D3 ELISA 
Tube S4 S3 S2 S1 S0 
Concentration 
(fmol/L) 
5000 4000 2000 1000 0 
S4 (μL) 0 160 80 40 0 
Sample 
Diluent (μL) 
0 40 120 160 200 
2.3.3.2.3 Reagent Preparation 
High Value Control (HVC): Reconstitute with 0.5mL of de-ionized water. Mix 
thoroughly and then allow it to sit for 15 minutes. Dilute reconstituted high value 
control 1:40 with standard diluent. 
Middle Value Control (MVC): Reconstitute with 0.5mL of de-ionized water. Mix 
thoroughly and then allow it to sit for 15 minutes. Dilute reconstituted middle 
value control 1:40 with standard diluent. 
 
2.3.3.3 General Assay Procedure for 25-hydroxyvitamin D3 and 1,25-
dihydroxyvitamin D3 
1. Remove the required number of well strips. 
2. Set one blank well with no solution. 
3. Add 50μL of standard, control and diluted sample to pre-determined well. 
Then add 50μL of HRP-conjugate immediately to each well. Mix gently 
by shaking plate for one minute. 
4. Cover with plate sealer and incubate for one hour at 37°C. 
5. Aspirate and wash each well four times with 300μL of Wash Buffer (1X 
PBS, 0.1% Tween 20) using an autowasher (Thermofisher Scientific
TM
 
Wellwash Versa
TM 
Microplate Washer). 
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6. Add 50μL of substrate A and 50μL of Substrate B to each well. Then 
incubate for 15 minutes at 37°C. Protect from light. 
7. At end of incubation add 50μL of Stop Solution to each well and tap plate 
gently to mix. 
8. Within five minutes read the optical density (OD) using a microplate 
reader (Thermofisher Scientific
TM
 Multiskan Go
TM  
Microplate 
Spectrophotometer) set to 450nm. 
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Chapter Three: Results 
 
3.1 ELISA Results 
3.1.1 25-hydroxyvitamin D3 Concentrations 
The mean serum 25(OH)D3 level was 69.34nmol/L (range=19.21-129.59nmol/L, 
n=51) and median 71.31nmol/L for all samples across the 54 week period. A total 
of 14 out of 51 samples (27.45%) had deficient serum 25(OH)D levels 
(<50nmol/L), of which only four samples (7.84%) were severely deficient 
(<30nmol/L). Insufficient 25(OH)D levels (50-75nmol/L) were identified in 13 
out of 51 samples (25.49%). A total of 24 (47.06%) of the samples had sufficient 
25(OH)D levels >75nmol/L. Therefore 52.9% of all samples had suboptimal 
vitamin D levels.    
 
 
Figure 12 Graph showing the breakdown of bronchiectasis serum samples with their 
25(OH)D cut-off points 
The mean sputum 25(OH)D3 level was 15.53nmol/L (range=4.83-31.88nmol/L, 
n=50) and the median 14.40nmol/L. There was a significant difference (p=0.0000) 
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between the total mean serum and sputum 25(OH)D3 concentrations (Figure 13). 
The Paired T-test further supported the significant difference between serum and 
sputum. Using just the control samples there was a significance found between 
visit one serum and sputum (p=0.0000001), and between visit six serum and 
sputum (p=0.0001) (Figure 14).  
 
Figure 13 Graph showing the overall serum and sputum 25(OH)D3 concentrations for all 
possible samples 
 
 
Figure 14 Graph showing control serum vs. sputum 25(OH)D3 concentrations 
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The 25(OH)D3 sputum levels (Figure 15) followed a similar trend to the 
25(OH)D3 serum levels (Figure 12). Levels were estimated and only used for 
providing a comparison; they are not true consensus levels. 
 
 
Figure 15 Graph showing the breakdown of bronchiectasis sputum samples with their 
estimated 25(OH)D cut-off points 
 
3.1.2  1,25-dihydroxyvitamin D Concentrations 
The overall mean serum concentration for 1,25(OH)2D3 over a period of 54 weeks 
is 49.18pmol/L (range=13.17-94.57pmol/L, n=54) and the median 48.08pmol/L . 
The overall mean sputum 1,25(OH)2D3 concentration over a period of 54 weeks is 
13.48pmol/L (range=0.82-42.96, n=53) and the median 12.25pmol/L. The mean 
values for serum and sputum can be seen in Figure 16 and are statistically 
significant (p=0.0000).  
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Figure 16 Graph showing the overall serum and sputum 1,25(OH)2D3 concentrations for all 
possible samples 
The use of a Paired T-Test further confirmed that the 1,25(OH)2D sputum levels 
are significantly lower than in serum. This was achieved by analysing only the 
serum and sputum baseline periods (Visit 1 & 6) (Figure 17). The significance 
between visit one serum and sputum was p=0.00000064 and between visit six 
serum and sputum was p=0.000007. 
 
Figure 17 Graph showing control serum vs sputum 1,25(OH)2D3 concentrations 
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3.1.3  25-hydroxyvitamin D3 vs 1,25-dihydroxyvitamin D3 
Association 
There was a correlation found between serum 25(OH)D3 levels and serum 
1,25(OH)2D3 levels (rho=0.6910, p=0.00000008) using Spearman’s non-
parametric correlations. This indicates the presence of a strong positive correlation 
between serum 25(OH)D3 and serum 1,25(OH)2D3 levels. The p-value was 
determined using a Paired T-Test, using only paired samples from all visits (total 
of 47 paired samples). The mean serum level of these paired samples was 68.24 
+/- 25.84nmol/L for 25(OH)D3 and 49.84 +/- 19.35pmol/L for 1,25(OH)2D3.       
 
Spearman’s non-parametric correlation revealed no correlation between serum 
25(OH)D levels and sputum 1,25(OH)2D levels (rho=-0.1560). But 1,25(OH)2D 
sputum levels are significantly lower than 25(OH)D serum levels (p=0.0000). The 
p-value was determined using a Paired T-Test using all paired samples from all 
visits, using a total of 45 paired samples. The mean level of these paired samples 
was 68.65 +/- 25.62nmol/L for 25(OH)D serum and 13.54 +/- 7.37pmol/L for 
sputum 1,25(OH)2D.       
 
3.1.4  Cathelicidin Concentrations 
Two separate commercially available ELISA kits were used in the determination 
of cathelicidin concentrations. When the data produced by the two separate kits 
are compared the results do not correlate. This may be due to the two ELISA kits 
measuring different components of parts of the active LL-37 or cathelicidin.  
 
3.1.4.1 Correlation between Hycult LL-37 vs USCNK CAMP Levels 
Performed a Spearman’s Rank Correlation between these two kits serum levels 
and expected that the levels should at least relate to each other. A total of 23 
sample pairs were used in the correlation. A very weak negative correlation was 
found (rho=-0.1413) between LL-37 serum levels and CAMP serum levels. 
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3.1.4.2  Hycult LL-37 ELISA Concentration 
The mean serum cathelicidin concentration was 57.54ng/mL (range=23.32-
127.36ng/mL, n=38) and a median of 50.44ng/mL. Only two sputum samples 
(duplicates) were run on this plate. One sputum sample was 1971.26ng/mL 
(respective serum value=49.96ng/mL) and the other sputum sample was 
2396.59ng/mL (respective serum value=33.13ng/mL). This produces a difference 
of 39-fold and 72-fold respectively, between serum and sputum levels for these 
two samples.  
3.1.4.3  USCNK CAMP ELISA Concentration 
The mean serum CAMP concentration was 569.12ng/mL (range=89.41-
1760.61ng/mL, n=32) and median of 412.67ng/mL. The mean sputum CAMP 
concentration was 60,443.29ng/mL (or 60.44μg/mL) (range=605.96-
196545.71ng/mL). The median CAMP sputum level was 55,728.44ng/mL (or 
55.73ug/mL). The difference between these two means was statistically 
significant (p=0.00000001) (Figure 18). This indicates an average 106-fold 
increase in sputum levels, compared to serum levels. Limited paired samples were 
available to carry out Paired T-Test. No significant difference (p=0.125) was 
found in CAMP serum levels across visits 1-5. 
 
 
Figure 18 Total average serum vs sputum CAMP concentration for all possible samples 
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3.1.5  β-defensin 2 Concentrations 
From all possible samples the total average concentration for hBD-2 was 
estimated. The total average serum concentration across the 54 week period is 
98.68pg/mL (range=8.05-325pg/mL, n=56) and median 72.88pg/mL. The average 
total sputum concentration is 165.79pg/mL (range=30.07-574.20pg/mL, n=52) 
and median 129.76pg/mL. The mean was 246.71pg/mL (range=30.07-2121.03 , 
n=55) and median 136.84pg/mL if the outlier has been included. The outlier 
individual has very high hBD-2 sputum concentrations at visit five 
(1090.66pg/mL), visit six (2121.03pg/mL) and visit nine (1493.29pg/mL) that 
were skewing the other remaining data. This data reveals a significant difference 
between serum and sputum hBD-2 concentrations (p=0.0044) (including outlier) 
and still significant if outlier removed (p=0.0026).  
 
 
Figure 19 Graph of the total average hBD- 2 serum and sputum concentrations (outlier 
inclusive) 
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n=11). If the outlier was removed from calculations there was a significant 
difference found between visit six serum and sputum concentrations (p=0.006976, 
n=10) (Figure 20).  
 
Figure 20 Graph of control serum vs sputum hBD-2 concentrations (outlier removed) 
 
3.1.6  Correlation Between Cathelicidin and β-defensin 2 
 Spearman’s non-parametric correlation coefficient was calculated to determine if 
any correlations exist between cathelicidin and hBD-2 concentrations. Both 
Hycult LL-37 and USCNK CAMP concentrations were used for analysis. A 
strong positive correlation (rho=0.633083) was found between hBD-2 serum and 
CAMP sputum levels (Figure 22). A moderate negative correlation (rho=-0.44273) 
was found between LL-37 serum and hBD-2 serum level (Figure 21).   
 
Table 4 Spearman correlation coefficient (number of pairs) for hBD-2 and cathelicidin 
 LL-37 Serum CAMP Serum CAMP Sputum 
hBD-2 Serum -0.44273 (36) 0.05495 (29) 0.633083 (20) 
hBD-2 Sputum -0.19132 (35) 0.00462 (25) 0.120301 (20) 
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Figure 21 A moderate negative correlation exists between LL-37 and hBD-2 concentrations 
 
 
Figure 22 A strong positive correlation exists between hBD-2 serum and CAMP sputum 
concentrations 
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3.1.7 Association of Vitamin D and Antimicrobial Peptides 
3.1.7.1.1 LL-37 Association with Vitamin D Metabolites 
Spearman rank correlation has revealed a very weak correlation between serum 
LL-37 levels and serum 25(OH)D levels (rho=-0.04813) or sputum 25(OH)D 
levels (rho=0.154786). No associations have been found with either 1,25(OH)2D 
serum (rho=-0.20244) or 1,25(OH)2D sputum levels (rho=0.160275). 
 
3.1.7.1.2 CAMP Association with Vitamin D Metabolites 
The association between CAMP concentrations and the measured vitamin D 
metabolites was assessed using Spearman’s Rank Correlation. This revealed only 
weak associations between serum and sputum CAMP and vitamin D (Table 5). A 
moderate positive correlation (rho=0.497403) was found between CAMP sputum 
levels and 1,25(OH)2D sputum levels (Figure 23). 
   
Table 5 Spearman correlation coefficient (number of pairs) for CAMP and vitamin D 
metabolites 
 CAMP Serum CAMP Sputum 
25(OH)D Serum -0.3287 (24) -0.015038 (20) 
25(OH)D Sputum 0.193846 (26) 0.323377 (21) 
1,25(OH)2D Serum -0.30037 (26) 0.062308 (25) 
1,25(OH)2D Sputum -0.03297 (27) 0.497403 (20) 
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Figure 23 A moderate positive correlation exists between 1,25(OH)2D and CAMP sputum 
concentrations 
 
3.1.7.2 β-defensin 2 Association with Vitamin D Metabolites 
Spearman’s rank correlation has revealed that only weak correlations exist 
between any of the measured vitamin D metabolites concentrations and hBD-2 
concentrations. All rho values indicate a very weak correlation (Table 6). 
 
Table 6 Spearman correlation coefficient (number of pairs) for hBD-2 and vitamin D 
metabolites 
 hBD-2 Serum hBD-2 Sputum 
25(OH)D Serum 0.051252 0.063425 
25(OH)D Sputum -0.1215 0.044475 
1,25(OH)2D Serum -0.00734 -0.09424 
1,25(OH)2D Sputum -0.01284 0.026334 
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3.1.7.3 Tertiles 
The data underwent a log transformation to enable further statistical analysis to be 
done. The data now adopts a normal distribution meaning that parametric tests can 
now be used. Tertiles are required for grouping 1,25(OH)2D3, LL-37, CAMP and 
hBD-2 which have no standardised concentrations. These AMP tertile groups 
were then compared to their samples corresponding vitamin D status (serum 
25(OH)D3 concentration) (VDD-Figure 24, VD insufficiency-Figure 25, VD 
sufficiency-Figure 26). 
 
 
Figure 24 Relationship between percentage of vitamin D deficiency (<50nmol/L) and the 
concentrations of hBD-2, LL-37 and CAMP 
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Figure 25 Relationship between percentage of vitamin D insufficiency (50-75nmol/L) and the 
concentrations of hBD-2, LL-37 and CAMP 
 
 
Figure 26 Relationship between percentage of vitamin D sufficiency (>75nmol/L) and the 
serum concentrations of hBD-2, LL-37 and CAMP 
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were then compared to the AMP tertile levels of LL-37, hBD-2 and CAMP 
(Figure 27, Figure 28, Figure 29). 
 
Figure 27 Relationship between percentage of low serum 1,25(OH)2D (Tertile 1) and the 
serum concentrations of hBD-2, LL-37 and CAMP 
 
 
Figure 28 Relationship between percentage of moderate serum 1,25(OH)2D (Tertile 2) and 
the serum concentrations of hBD-2, LL-37 and CAMP 
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Figure 29 Relationship between percentage of high serum 1,25(OH)2D (Tertile 3) and the 
serum concentrations of hBD-2, LL-37 and CAMP 
 
The tertile values of 1,25(OH)2D in sputum were then compared with the AMP 
sputum levels (Figure 30, Figure 31 & Figure 32). Only hBD-2 and CAMP has 
measured sputum levels available for analysis.
 
Figure 30 Relationship between percentage of low sputum 1,25(OH)2D (Tertile 1) and the 
sputum concentrations of hBD-2 and CAMP 
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Figure 31 Relationship between percentage of moderate sputum 1,25(OH)2D (Tertile 2) and 
the sputum concentrations of hBD-2 and CAMP 
 
 
Figure 32 Relationship between percentage of high sputum 1,25(OH)2D (Tertile 3) and the 
sputum concentrations of hBD-2 and CAMP 
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3.1.8  Procalcitonin Concentrations 
The total mean serum concentration was 62.88pg/mL (range=8.22-733.08pg/mL, 
n=41) and the median 28.06pg/mL (0.02806ug/L). The removal of one major 
outlier (visit 5 serum sample) changed the mean to 46.13pg/mL (range=8.22-
179.79pg/mL, n=40). The one major outlier in this data was for a visit five serum 
sample, which had a recorded PCT level of 733.08pg/mL (0.73308μg/L). This 
level is over 0.5ug/L which is commonly used in studies to indicate the presence 
of a strong bacterial infection that should be administered antibiotics [148]. The 
total mean sputum PCT concentration was 268.17pg/mL (range=60.64-
697.48pg/mL, n=49) and the median 211.39pg/mL (0.21139ug/L). A t-test reveals 
a high significance (p=0.000000007) between serum PCT and sputum PCT as 
seen on Figure 33.  
 
 
Figure 33 Graph showing total average PCT concentration in serum* and sputum of 
bronchiectasis patients (*outlier omitted) 
 
Only the baseline levels (Visit 1 & 6) were used for determining if there is any 
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found between serum and sputum levels for both baselines visit one (p=0.01, n=11) 
and visit six (p=0.04, n=5) further supporting the overall findings. The mean 
values for these control periods can be seen below on the graph. This graph 
further emphasises the difference between serum and sputum PCT concentrations 
(Figure 34). 
 
 
Figure 34 Graph of control (visits 1 and 6) serum vs sputum PCT concentrations 
 
Samples were broken down into predetermined cut-off levels of PCT. The lowest 
PCT level indicating no bacterial infection was 0.1ug/L (100pg/mL). A total of 35 
out of 41 samples (85.37%) fell into this low PCT level. The next most prevalent 
group (12.20%) was moderate PCT levels (between 0.1-0.5ug/L or 100-500pg/mL) 
indicating a possible bacterial infection. Only one individual (2.44%) presented 
with a high PCT level above 0.5ug/L (500pg/mL) strongly indicating the presence 
of a bacterial infection. 
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Figure 35 Graph showing the breakdown of samples into predetermined PCT cut-off points 
 
3.1.8.1 Procalcitonin Correlation With Other Analytes 
Spearman’s non-parametric correlations were used to determine if there was any 
relationship between serum or sputum PCT and the other measured analytes. 
Cathelicidin, 25(OH)D and 1,25(OH)2D only showed weak correlations with PCT 
serum or sputum levels. Strong positive correlations were found between PCT and 
hBD-2 in both serum (rho=0.607, n=33) and sputum (rho=0.671, n=44) 
bronchiectasis samples as can be seen observed in their respective scatterplots 
below (Figure 36 & Figure 37).  
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Figure 36 A strong positive correlation exists between PCT and hBD-2 serum concentrations 
 
 
Figure 37 A strong positive correlation exists between PCT and hBD-2 sputum 
concentrations 
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3.1.9 Tiotropium Treatment Effect Analysis 
3.1.9.1 25-hydroxyvitamin D 
No significant difference was found across the two crossover periods of the 
ROBUST trial. A Paired T-test showed no significance in serum concentrations 
between visits 1-5 (p=0.10) or visit 6-9 (p=0.07). The same for sputum 
concentrations, visit one to five (p=0.34) and visit six to nine (p=0.52). 
3.1.9.2 1,25-dihydroxyvitamin D 
A significant difference was found across the both of the crossover periods of the 
ROBUST trial. A Paired T-Test has shown a significant difference in serum 
concentrations across both crossover periods, visit 1-5 (p=0.0028) and visit 6-9 
(p=0.000484) of the clinical trial (Figure 38). No significance was identified 
across sputum concentrations. Only paired data was included in the T-Test, so 
some previously included samples excluded.  
 
 
Figure 38 Graph of 1,25(OH)2D average serum concentration for whole clinical trial  
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3.1.9.3 Cathelicidin 
For the Hycult LL-37 ELISA kit, a Paired T-Test showed no significance was 
across visits 1-5 serum (p=0.9500) concentrations. A p-value of less than 0.05 was 
found across visit 1-9 (p=0.0041) serum levels but the sample number was very 
limited (n=4 pairs). Limited paired samples available to carry out Paired T-Test 
on the USCNK CAMP ELISA. No significant difference was found (p=0.125) 
between CAMP serum levels across visits 1-5. Not enough sputum pairs available 
for sputum Paired T-test analysis. 
 
3.1.9.4 β-defensin 2 
Using a Paired two-tailed T-Test (Table 7) there was no identified significant 
differences in hBD-2 concentrations across each half (Visit 1-5 and Visit 6-9) of 
the clinical trial in serum or sputum (Table 7). Only data that were paired were 
analysed, some previously used samples therefore were excluded. The p-values 
once this outlier was excluded from the Paired T-Test can be seen in brackets in 
Table 7, but still no significance. The mean values for these control periods can be 
seen on the graph. 
 
Table 7 Paired T-test results for hBD-2 concentrations 
 Serum Sputum (removed outlier) 
 Visit 1/5  Visit 6/9 Visit 1/5 Visit 6/9  
p-value 0.49 0.83 0.18 (0.18) 0.56 (0.12) 
No. of Pairs 14 11 11 (10) 11 (10) 
 
3.1.9.5 Procalcitonin 
Using a paired two-tailed T-Test there was no identified significant differences 
found in PCT concentrations across each crossover half (visit 1-5 and visit 6-9) of 
the clinical trial, in serum or sputum. Only data that were paired were analysed, 
some previously used samples therefore were excluded. Statistical analysis of 
PCT samples was problematic due to difficulty with the kit in obtaining reliable 
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duplicates. No controls were provided with the ELISA kit. Therefore the number 
of paired samples for the Paired T-Tests is severely decimated.  
 
Table 8 Paired T-test results for PCT concentrations 
 Serum Sputum  
 Visit 1/5  Visit 6/9 Visit 1/5 Visit 6/9  
p-value 0.43 0.99 0.06 0.34 
No. of 
Pairs 
9 2 7 8  
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Chapter Four: Discussion 
 
4.1 Tiotropium Treatment Effect 
The samples used were collected as part of a clinical trial investigating the 
usefulness of Tiotropium for the treatment of non-cystic fibrosis bronchiectasis. In 
this double-blind crossover study, the participants were receiving Tiotropium for 
six months and a placebo for the other six months. Samples were collected at the 
onset and completion of each crossover period.  
Any significant differences found across this twelve month period in analyte 
concentration may indicate potential treatment effects. Paired T-tests were used to 
determine if any significant differences in analyte concentration occurred across 
each crossover period. No significant differences were detected for PCT, hBD-2 
and 25(OH)D3 serum or sputum concentrations across the twelve month trial. The 
use of a Paired T-test for cathelicidin was limited due to lack of paired samples. 
For the first crossover period, serum LL-37 and CAMP revealed no significant 
difference. A statistically weak difference (p=0.000484) was found across visits 
six to nine for serum LL-37 but this was from a limited sample size (n=4). A 
significant difference (p=0.0028 and p=0.000484) was found across both 
crossover periods for serum 1,25(OH)2D3. Seeing as this happened across both 
crossover periods it cannot be as a direct result of Tiotropium treatment. 
Potentially these observed differences are due to expected seasonal fluctuations in 
vitamin D concentrations. No differences were identified for 1,25(OH)2D in 
sputum. 
Our findings suggest that during this twelve month period there were no 
substantial identified differences in the analytes. Therefore we can declare that 
treatment with Tiotropium does not appear to influence our results. Unfortunately 
due to the ROBUST clinical trial still being in progress, the randomisation codes 
still remain blind.    
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4.2 Vitamin D 
Serum 25(OH)D concentration is the normal clinical measure of vitamin D status. 
Our research showed that sub-optimal vitamin D levels (<75nmol/L) are 
commonplace in bronchiectasis patient serum samples (52.9%). The median 
25(OH)D3 serum level of 71.31nmol/L for this stable non-cystic fibrosis 
bronchiectasis patient cohort, is not consistent with the only other study of VDD 
in bronchiectasis. During the course of this research, a paper was published by  
Chalmers et al., that reported a median 25(OH)D level of 24.7nmol/L with a total 
of 50% of their cohort being classed as vitamin D deficient (<25nmol/L), 
compared to 12% of their control group [43]. Our research only indicated a VDD 
rate of 27.45% based on a different cut-off for VDD (<50nmol/L). Our findings 
reject our hypothesis of VDD being prevalent in bronchiectasis patients. 
 
The potential reasons for this inconsistency could be the use of vitamin D 
supplementation. In the Chalmers et al. study a total of 16.9% of patients were 
excluded due to vitamin D supplementation use [43]. This was not assessed in our 
patient cohort. The timing of the sample collection in this clinical trial meant that 
there was an underrepresentation of samples collected during the winter months. 
The majority of samples were taken in spring and early autumn. Potentially the 
data therefore is not providing an accurate annual representation of vitamin D 
levels. 
 
Our 25(OH)D3 serum levels (71.31nmol/L) are higher than those reported for 
other  respiratory diseases. In community acquired pneumonia the median 
25(OH)D serum level was 54nmol/L [107]. But interestingly in patients identified 
as receiving vitamin D supplements, the median increased to 85nmol/L which is 
more consistent with our findings. Their study used the same cut-off points for 
VDD as our study (<50nmol/L), with severe VDD defined as <30nmol/L. Their 
total VDD rate was 44% compared to our 27.45%, and 15% compared to our 7% 
for severe VDD. Our data was also higher than the reported 25(OH)D serum 
levels in COPD 19.9ng/mL (49.67nmol/L); VDD was associated with the severity 
of disease in this instance [133]. 
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The median 25(OH)D3 sputum level was 14.40nmol/L, which was significantly 
lower (p=0.0000) than the serum 25(OH)D level. The same is true for 
1,25(OH)2D  serum and sputum concentrations (p=0.0000). These lower vitamin 
D metabolite sputum levels may be a result of transport limitations [117]. It is 
thought that because vitamin D metabolites have a high affinity for their carrier 
proteins (eg. DBP, albumin), with over 99% of vitamin D metabolites being 
bound within the blood [116], this may ultimately affect their transportation into 
airways [117]. Potentially concentrations are also limited by receptor binding 
affinity or the active transport of these metabolites into the epithelial cells [155]. 
No data is currently available on the presence of vitamin D metabolites in sputum 
for comparison. But lower concentrations of 25(OH)D and 1,25(OH)2D have been 
reported in BAL fluid (localised) compared to their respective serum counterparts 
[117]. 
 
The vitamin D metabolite, 1,25(OH)2D3, has been included in this study as 
previous studies focused on 25(OH)D have failed to show an association with 
AMP concentrations [43, 107]. Typically 1,25(OH)2D is not used to assess 
vitamin D status, as it has a very short half-life (approximately 4 hours) and its 
renal production is tightly regulated for bone health. 1,25(OH)2D is the active 
form and is the vitamin D metabolite that has been shown in vitro to directly 
upregulate various target genes, including AMP’s. Its non-renal synthesis in 
bronchial epithelial cells and immune cells is possible due to the required 
enzymatic machinery being present. It is therefore hypothesized that an in vivo 
association between 1,25(OH)2D and AMP’s concentrations may exist.  
 
The median 1,25(OH)2D3 serum concentration was 48.08pmol/L. But no 
standardised levels of 1,25(OH)2D have been determined. Two studies have 
reported slightly higher 1,25(OH)2D levels in serum compared to our study. In a 
healthy Danish population a reported level of 29.0pg/mL (69.6pmol/L) [153]and 
the other study a level of 23.6pg/mL (56.64pmol/L) in their control group [154]. 
This would indicate that our reported 1,25(OH)2D serum concentrations are lower 
than those reported in healthy cohorts. 
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Our study revealed a moderately strong positive correlation using Spearman’s 
non-parametric correlation, between serum 25(OH)D3 levels and serum 
1,25(OH)2D3 levels (rho=0.6910). This indicates that the level of serum 
1,25(OH)2D is most likely dependent on its substrates 25(OH)D concentration. 
But remarkably no correlation was found between 1,25(OH)2D3 sputum levels and 
serum 25(OH)D3 levels (rho=-0.1560). This may potentially indicate that these 
localized 1,25(OH)2D levels are under the control of some unknown local 
regulation, for example, growth factors or cytokines. Non-renal 1,25(OH)2D is not 
under the regulation of PTH like the renal form. But the active local 
concentrations are not fully dependent on their substrate concentration as expected. 
 
Evaluation of 25(OH)D3 and 1,25(OH)2D3 concentrations has revealed strong 
localised effects. The local concentrations of these metabolites are independent 
from the circulating serum vitamin D metabolites concentrations. Sub-optimal or 
insufficient vitamin D levels are prevalent in non-cystic fibrosis bronchiectasis. 
This may indicate causality, but more likely due to the fact that respiratory 
conditions lead to a reduced outdoor activity and therefore reduced sun exposure. 
Hypovitaminosis D is a consequence of living with a respiratory condition and not 
a causative factor [49, 108, 133, 156]. 
 
4.3 Vitamin D and Antimicrobial Peptides 
VDRE’s have been discovered in the promoter region for both of the genes for 
cathelicidin and hBD-2 [88]. It is known that the VDR-1,25(OH)2D-RXR 
complex is capable of regulating the expression of these genes via these VDRE’s, 
as shown in multiple in vitro studies [87, 88]. The hypothesis thereby exists that 
individuals with lower vitamin D levels would correspondingly have decreased 
AMP levels. This effect though has yet to be proven in vivo. The best way to 
detect any relationships between the vitamin D metabolites and AMP’s is using 
Spearman’s non-parametric correlations.  
 
All comparisons between LL-37, CAMP and hBD-2 concentrations with 
25(OH)D3 or 1,25(OH)2D3 serum and sputum concentrations, have revealed very 
weak correlations. Except for the moderate positive correlation found between 
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CAMP sputum levels and 1,25(OH)2D sputum levels (rho=0.497). One study has 
reported similar findings with a moderate association being found between 
hCAP18 and 1,25(OH)2D plasma levels but again a weak correlation between 
hCAP18 and 25(OH)D [106].  
 
hBD-2 and LL-37 failed to support the hypothesis of lower vitamin D levels being 
associated with correspondingly low AMP levels. This is evident when data was 
log-transformed and broken down into tertiles (Section 0). LL-37 and hBD-2 
showed no trends with 25(OH)D3 or 1,25(OH)2D3 cut-off points or tertiles. Only 
CAMP sputum showed this trend with 1,25(OH)2D sputum, with only the two 
higher CAMP tertiles (2 and 3) being found in the highest 1,25(OH)2D tertile 
(tertile 3) (Figure 32). This further emphasises the above finding of a moderate 
positive association (rho=0.497) between CAMP sputum and 1,25(OH)2D3 
sputum. 
 
But other previous studies have also failed to find any association either LL-37 or 
hBD-2 with serum 25(OH)D. The suggestion was made that LL-37, the active 
peptide fragment, may not be the most suitable measure. The prepropeptide, 
which is normally cleaved by enzymes to release active LL-37, may provide more 
insight [107]. Our data supported this as no correlations were identified between 
LL-37 and vitamin D metabolites. These results indicate that focusing on the 
active form 1,25(OH)2D may be more valuable in identifying these associations 
with AMP’s in vivo. 
 
The recent Chalmers et al. paper also failed to find an association between serum 
25(OH)D and LL-37 sputum concentrations in bronchiectasis patients. In fact this 
paper actually identified higher LL-37 sputum levels in VDD individuals [43]. 
Interestingly, our data revealed a trend between the highest serum LL-37 tertile 
(Tertile 3) and VDD. LL-37 serum (Tertile 3) was the largest group in VDD 
(18.18%) and the largest represented grouping overall (Figure 24). Unfortunately 
that paper failed to report their actual mean or median sputum LL-37 values so 
unable to compare these findings [43]. This suggests that vitamin D effects in vivo 
have little effect on LL-37 level. The relationship between DBP in the airway and 
neutrophil mediated inflammation may be a more important mechanism in the 
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link between vitamin D and disease severity. High levels of DBP in sputum are 
associated with airway inflammation and disease severity in bronchiectasis [43].  
  
The in vitro studies of 1,25(OH)2D treatment on various cell-lines showed strong 
upregulation of CAMP expression but only a modest effect on hBD-2 levels [88]. 
Consequently it is not surprising that hBD-2 failed to show any association with 
the vitamin D metabolites in vivo. The finding of a positive correlation between 
CAMP sputum levels and 1,25(OH)2D sputum levels in vivo supports the findings 
of the in vitro experiments.  
  
4.4 Cathelicidin 
Two separate ELISA kits were used to analyse cathelicidin levels. The median 
serum LL-37 level was 50.44ng/mL. This is nearly identical to a reported LL-37 
median serum level in tuberculosis patients of 49.5ng/mL [157]. In a similar study, 
that was using the same ELISA kit, they reported a median level of 69ng/mL in 
community-acquired pneumonia [107]. Our reported serum LL-37 value is 
slightly lower but still fairly consistent. The only valid control LL-37 serum 
concentration available was a prior study to the above tuberculosis study. The 
study reported a mean serum 27.21ng/mL in a healthy outpatient cohort [105]. 
Therefore it appears that serum LL-37 is elevated in a number of these chronic 
respiratory conditions, including in our bronchiectasis cohort. Potentially LL-37 
could act as an indicator of an amplified immune activation involved in the 
chronic infection progression of these conditions [157].   
 
The Leow et al., 2001 study identified that cathelicidin concentrations did not 
tend to drop after an acute admission. Follow-up levels remained similar to 
admission levels [107]. Our study found no statistical robust difference 
(p=0.950002) between LL-37 between visit one and five samples. Patient samples 
tended to remain consistent over the course of the clinical trial. This indicates that 
cathelicidin levels may be influenced by more than an acute exacerbation; other 
factors may be involved. Again no standardised normal serum level of LL-37 has 
been established, so without a control population it is difficult to detect if directly 
compare if levels are elevated or not.  
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Interestingly, no correlation was found between the LL-37 levels and the CAMP 
levels (rho=-0.1413). This may be because the two kits are measuring different 
cathelicidin components. Unfortunately the CAMP ELISA kit failed to state 
exactly what it was measuring. It is unknown if the USCNK assay was measuring 
the precursor of cathelicidin (hCAP18) or the active peptide component LL-37, or 
both. The median CAMP serum level was 412.67ng/mL and the median CAMP 
sputum level was 55.73μg/mL, showing a 106-fold increase. The CAMP sputum 
level was statistically higher (p=0.00000001) than the CAMP serum level. Two 
sputum samples were run on the USCNK LL-37 kit, these samples showed a 39-
fold and 72-fold increase over their respective serum equivalent. This data 
indicates that serum cathelicidin levels are not representative of what is happening 
at localised sites in bronchiectasis.  
 
Most often hCAP18 or LL-37 levels are measured in plasma, which is not directly 
comparable with serum levels. There is a scarcity of valid comparable data for our 
study. Reported mean plasma hCAP18 levels in control groups are 1180+/-
200ng/mL in a Denmark volunteers [98] and  650+/-343ng/mL in control patients 
of a haemodialysis study [106]. These values appear to fit better with our CAMP 
serum mean of 569.12ng/mL, suggesting that this ELISA kit may in fact be 
measuring cathelicidin precursor levels. Our mean is lower than both of these 
control groups.  
 
There is a lack of data investigating localised cathelicidin levels compared to 
circulating levels. In BAL fluid, the measured LL-37 levels are lower than the 
serum LL-37 concentrations [117]. This is opposite to the high localised levels 
found in sputum of our bronchiectasis cohort. Higher localised cathelicidin levels 
are expected due to their natural role in host defense and consistent with 
bronchiectasis being a localised condition. One study has investigated sputum LL-
37 levels in bronchiectasis but unfortunately this paper failed to report their mean 
or median concentration [43]. In COPD, LL-37 in induced sputum has been 
shown to be elevated compared to two control groups (healthy smokers and 
healthy non-smokers) [158]. hCAP18 has been shown in both CF and COPD to be 
elevated in induced sputum when compared to serum counterparts and control 
groups [159, 160]. Our median CAMP sputum level was 55,728.44ng/mL 
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(55.72ug/mL); still higher than their reported level of 79,623pg/mL in CF and 
75,262pg/mL in COPD [159].    
 
Investigations have indicated a possible synergistic relationship between LL-37 
and hBD-2 [94, 95]. This concept has been supported by animal sepsis models in 
which hCAP18 have been capable of initiating the release of inducible defensins 
[161, 162]. The use of Spearman’s non-parametric correlations revealed potential 
relationships between cathelicidin and hBD-2. A strong positive correlation 
(rho=0.633083) was found between hBD-2 serum and CAMP sputum levels. This 
indicates that as the levels of CAMP increase in the sputum, so do the hBD-2 
levels in circulation. A moderate negative correlation (rho=-0.44273) was found 
between serum LL-37 and serum hBD-2, therefore as the level of one increases 
the level of the other decreases. All the other correlations between cathelicidin and 
hBD-2 serum or sputum revealed weak correlations. These two potential 
relationships reveal a possible interaction between these two AMPs against 
infection. More research is needed into further refining these relationships.  
 
Additionally, other elements may be contributing to the regulation of cathelicidin 
levels. Cathelicidin, like other AMPs, have numerous functions in addition to its 
antimicrobial properties. Cathelicidin is known to recruit important immune cells, 
neutrophils, monocytes, leucocytes and T cells, to sites of inflammation [117]. 
High concentrations of sputum LL-37 has been correlated with Pseudomonas 
aeruginosa colonization [117]. In future studies it may be worthwhile to culture 
sputum and look at the pathogens isolated.   
 
The overall cathelicidin findings indicate elevation of serum LL-37 levels in 
bronchiectasis when compared to control cohorts. But the CAMP serum levels 
appear to be decreased in bronchiectasis, but there are only plasma hCAP18 
control levels available for comparison. In general, cathelicidin levels remain 
steady in these stable bronchiectasis patients. Higher sputum levels have 
supported the notion of elevated localised cathelicidin levels in bronchiectasis. 
This finding is consistent with bronchiectasis being a localised disease that is 
characterised by frequent acute pulmonary exacerbations. 
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4.5  β-defensin 2 
The finding of a significant difference (p=0.0044) between serum and sputum 
levels of hBD-2 is not surprising. The median serum level was 72.88pg/mL 
compared to the median sputum level of 136.84pg/mL, showing that hBD-2 levels 
are elevated in sputum of bronchiectasis patients. The AMP hBD-2 is produced 
chiefly by epithelial cells and is known to be secreted by the bronchial epithelial 
cells. Therefore, one would expect that the serum concentration would not 
accurately represent local hBD-2 levels in bronchiectasis. But contrastingly other 
studies have found a good correlation between both plasma (systemic) and BAL 
fluid (localised) defensin levels in pneumonia [163, 164]. Unfortunately, there are 
currently no studies on hBD-2 levels in bronchiectasis.  
 
The existing studies on hBD-2 levels in various respiratory conditions provide 
conflicting results. Again there is no consensus on normal healthy hBD-2 levels. 
In community-acquired pneumonia the median serum hBD-2 level was 262pg/mL 
[107] which is considerably higher than our reported value (72.88pg/mL) for 
bronchiectasis. In COPD, the level of hBD-2 in the sputum supernatant fell below 
the lowest limit of detection (<8pg/mL) for the ELISA. The two control groups 
for this study reported mean levels of 98pg/mL in healthy smokers and 74pg/mL 
in never-smokers [165]. Our mean sputum (246.71pg/mL) finding is substantially 
higher than these two control groups.      
 
Panbronchiolitis (DPB) is a respiratory disease very similar to bronchiectasis, and 
is in fact one of its identified aetiologies. DPB is similar to bronchiectasis in a 
number of ways including the frequent periods of infection, chronic inflammation 
and colonization by Pseudomonas aeruginosa and Haemophilus influenzae in the 
sputum. Even with these similarities their findings show again the opposite to our 
study, with higher systemic hBD-2 level (plasma-167.6pg/mL) than in BAL fluid 
(71.5pg/mL) in DPB patients; both significantly higher than their control groups 
[166].  
 
All these inconsistencies indicate that other factors must be influencing hBD-2 
levels. Stronger stimulation of hBD-2 expression is reported when 1,25(OH)2D is 
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in the presence of IL-1β [167]. This signalling pathway works via TLR1/2 (PRP) 
to induce expression of IL-1β in monocytes. The signalling by IL-1β to enhance 
1,25(OH)2D’s effect most likely due to binding by the transcription factor NF-κB 
to specific binding site in hBD-2 promoter [168]. Therefore analysing IL-1β 
concentrations might be beneficial. 
 
One study on sputum hBD-2 levels in acute pneumonia revealed suppressed levels 
of hBD-2 in both sputum and pharyngeal washes in individuals who smoke or are 
ex-smokers [169]. Smoking therefore is linked to an increased susceptibility of an 
individual to infection. Knowing our patient cohorts smoking status may have 
enable further investigation into this association. The expression of hBD-2 has 
been also shown to be inducible during infections or inflammation. Even though 
hBD-2 is the most highly expressed defensin in the lung, there are multiple other 
human defensins that also may overlap in the same tissues. Possibly some 
defensins may be capable of substituting for hBD-2. 
 
No conclusion can be made on the role of hBD-2 in the pathology of chronic 
respiratory tract infections. Our novel finding of higher localised levels of hBD-2 
seems to be inconsistent with reports for other respiratory conditions. Being the 
only study so far investigating hBD-2 concentrations in bronchiectasis, further 
analysis is needed for confirmation. The possibility exists that sputum samples are 
potentially contaminated by saliva during sputum collection, in which high 
defensin levels are present.  
 
Both of the AMP’s, cathelicidin and hBD-2, showed statistically elevated 
concentrations in the sputum compared to serum. AMP’s normal role is to 
function in the innate immune system to provide host defence. Bronchiectasis is 
known to be a localised rather than systemic condition; therefore one would not 
expect a flowover effect to be seen in the serum. 
 
4.6  Procalcitonin 
Bronchiectasis patients frequently experience reoccurring LTRI’s [3]. Preventing 
these exacerbations is vital to increasing the patient’s management of the 
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condition, quality of life and decreasing the disease progression. Current 
treatments are based on extrapolations for the treatment of other respiratory 
conditions. Finding a suitable inflammatory marker for bronchiectasis may aid in 
guiding antibiotic treatment. Currently no suitable systemic inflammatory marker 
exists for these exacerbations in bronchiectasis. 
 
Studies suggest that stable patients with non-cystic fibrosis bronchiectasis have 
consistently elevated systemic markers of inflammation. This has been reported 
with two systemic inflammatory markers, CRP and ESR [139]. PCT is a new 
inflammatory marker that has proven useful in the detection of bacterial infections 
[141]. Due to these frequent bacterial exacerbations in bronchiectasis, one would 
expect both systemic and local inflammatory markers to be elevated, even during 
a stable state [137, 140].  Therefore it was expected that both PCT serum and 
sputum levels would be elevated in this patient cohort. 
 
Results show that serum PCT levels appear to be very low and therefore not 
consistently elevated in stable bronchiectasis patients. The median PCT level 
reported in COPD was 0.096ug/L [142] and 0.57ug/L in pneumonia patients [149]. 
The median PCT serum value in this study was only 0.028ug/L for stable 
bronchiectasis patients. This value aligns bronchiectasis more closely to COPD 
than pneumonia. Both COPD and bronchiectasis are more localized diseases, with 
infection and inflammation generally being limited to the mucus linings of the 
respiratory tract.  
 
The only other study that has reported PCT serum levels in bronchiectasis 
revealed a median of 0.055ug/L [138]. Our reported median serum PCT level is 
slightly lower than this. Both these values are under 0.1ug/L, which is generally 
used to indicate no bacterial infection (clinical sepsis) and no requirement for 
antibiotics. A total of 14.63% of our samples recorded PCT levels above this 
0.1ug/L threshold; compared to the only other study which had 21.1% above 
[138]. But potentially these results are influenced by a high proportion of patients 
in that study receiving prophylactic antibiotics. 
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Without comparing to actual acute exacerbations a conclusion cannot be made on 
the suitability of PCT in managing bronchiectasis exacerbations. Some patients 
did show higher PCT levels at specific visits but not consistently higher over the 
54 weeks. It would have been advantageous to match these higher PCT levels 
with actual acute exacerbations or sputum bacteriology. But it is clear that PCT is 
not constitutively elevated in the serum of stable bronchiectasis patients. 
Potentially the reason that serum PCT is not consistently elevated is that all 
exacerbations may not be the result of bacterial infections, or these infections may 
be localized within the bronchial tissue.  
 
PCT sputum levels are significantly higher (p=0.000000007) than in serum which 
is consistent with bronchiectasis being a very localized rather than systemic 
condition. The median sputum PCT level is 0.21139ug/L (0.21139ng/mL) 
compared to the median PCT serum level of 0.02806ug/L (0.02806ng/mL). This 
significance was detected over both control periods (V1, p=0.01 and V6, p=0.04) 
as well as over the whole 54 weeks. Unpublished data supports these elevated 
PCT levels being present in sputum (2ng/mL) against serum (<0.5ng/mL) in 
bronchiectasis patients with acute exacerbations (Wong et al., 2011). 
Unfortunately no published research is available on the function and concentration 
of normal PCT in sputum. Elevated PCT sputum levels are expected though, as 
sputum contains a higher density of both bacteria and inflammatory cells.  
 
There was a major issue with the reproducibility of the PCT ELISA kit. 
Duplicates were difficult to obtain even though no dilutions were needed. 
Therefore the %CV required was increased to 40% to enable enough data to be 
used for statistical analysis. Even then a large number of samples could not be 
included in the results. These ELISA kits are generally set up to detect any 
abnormally high PCT levels. Many of the samples had very low OD values (>0.2) 
which unfortunately places them at the most inaccurate point of the standard curve. 
The use of triplicates may have aided in obtaining more consistent results. 
 
An interesting comparison would be between PCT and CRP levels in 
bronchiectasis during and after acute exacerbations. CRP is typically associated 
with systemic inflammation and PCT with bacterial infections. PCT has many 
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properties that make it more desirable, peaking at just over 8 hours from initial 
infection. PCT has been shown to have better specificity and sensitivity than CRP 
during an episode of bacterial infection [147]. An interesting strong positive 
correlation found was between both PCT and hBD-2 serum (rho=0.607) and 
sputum levels (rho=0.671). The potential mechanism behind this relationship is 
unknown and may warrant further investigation. The overall PCT findings show 
that serum PCT is not elevated in stable bronchiectasis patients, however is 
significantly elevated in localised respiratory levels. 
 
4.7 Factors Influencing Vitamin D Levels 
There are several complexities that make the direct analysis of vitamin D status 
challenging. Firstly is the difficulty in determining 25(OH)D cut-off points for 
deficiency. Most currently accepted vitamin D cut-offs are based on those 
required for bone health with no regard for vitamin D’s pleiotropic actions. 
Another complicating issue when studying vitamin D is the numerous vitamin D 
metabolites that exist [60]. The commercial ELISA kits used in this research were 
based on the predominant vitamin D3 metabolites. The use of ELISA kits capable 
of measuring both D2 and D3 together will improve the accuracy of results. Finally, 
there are many genes involved in the transport and metabolism of vitamin D. The 
DBP and VDR genes have been well research and genetic variations have been 
linked to vitamin D bioavailability. These polymorphisms may ultimately effect 
1,25(OH)2D’s action on target genes.  
 
Vitamin D is a lipophilic molecule and therefore relies on plasma proteins for 
transportation to target cells. At any one time up to 99% of vitamin D metabolites 
are bound [116]. The primary carrier is DBP, with smaller amounts being carried 
by albumin. Being bound to DBP greatly extends the circulating half-life of 
25(OH)D [61, 116]. Studies have indicated that polymorphisms in the DBP gene 
(GC) may have an influence on the binding of vitamin D metabolites. Three 
common variants are GC1F, GC1S and GC2. The most well-known non-
synonymous isoforms are the SNP’s rs4588 and rs7041 [118]. The rs7041 (TT 
genotype) has been investigated in COPD and has been linked to lower 25(OH)D 
concentrations [133]. Variants in the GC gene (rs4588-AA allele) have also been 
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associated with an increased individual’s response to vitamin D supplementation 
[170].  
 
SNP’s of the GC gene have not only been linked to lower levels of 25(OH)D but 
also to higher levels of DBP [118, 171]. DBP has many other functions including 
actin binding, macrophage activation, and neutrophil chemotaxis [118, 133]. 
These factors are important as bronchiectasis is regarded as a neutrophil-driven 
disorder [25]. Neutrophils are the predominant cell type isolated from the airway 
fluid of bronchiectasis patients [172]. Elevated numbers of neutrophils exist in 
stable bronchiectasis patients and increase further with an exacerbation [173].       
 
The VDR is responsible for binding the ligand 1,25(OH)2D and forming a 
heterodimer with the RXR. This enables the binding to VDRE’s on target genes. 
Polymorphisms within the VDR gene will influence association with target genes 
(eg. CAMP and hBD-2) rather than circulating 25(OH)D levels. There are five 
common polymorphisms Cdx2, FokI, ApaI, TaqI and BsmI [174]. The VDR 
polymorphisms FokI (ff genotype) and TaqI (Tt genotype) is associated with the 
risk lower respiratory tract infections in young Canadian children [175]. The FokI 
f allele results in a VDR protein that is longer and functionally results in a lower 
rate of VDR transcription [176]. This f allele has also been associated with risk of 
multi-drug resistant tuberculosis [177].  
 
Another potential influential factor could be the active transport of 25(OH)D into 
the target cells. There are many other elements involved in the binding of 
1,25(OH)2D including protein kinase A (upregulates) or protein kinase C 
(downregulates). These can therefore have an impact on target gene expression. 
Transcription factors are also required to help bind the VDR-1,25(OH)2D-RXR 
complex to VDRE’s, for example, NF-κB [178]. Numerous additional factors 
need to be considered in the assessment of vitamin D concentrations. 
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4.8  Study Limitations 
Unfortunately sample number had to be restricted due to the cost and availability 
of commercially available ELISA kits. The majority of samples obtained from 
Auckland Hospital contained insufficient sputum volume to carry out all ELISA 
tests. The use of these samples therefore did not allow a complete data set to be 
obtained for these patients. The small sample size limits complex statistical 
analysis of results. Results could have been strengthened by the use of a healthy 
control population for direct comparison. Currently little data is available 
regarding normal serum or sputum levels of cathelicidin, hBD-2, PCT and 
1,25(OH)2D. 
 
A lack of provided medical history makes the analysis of results challenging. 
Bronchiectasis patients often experience frequent reoccurring exacerbations, and it 
was unknown whether any individuals experienced acute exacerbations during the 
clinical trial. For example, one individual showed a high PCT level 
(733.08pg/mL), this is over the suggested level of 0.5ug/L used to indicate a 
severe bacterial infection. Pulmonary function (eg. %FEV1) gives an insight into 
severity of bronchiectasis; VDD and AMP levels have been correlated with 
disease severity previously. Studies have also shown associations between 
mortality and VDD [107] as well as hCAP18 levels and mortality [106]. 
Nutritional status is also a big contributor for vitamin D concentration.   
 
In addition to these, smoking status may have provided some insight. Previously 
smoking has been associated with lower levels of hBD-2 in sputum [169]. Age 
and ethnicity are also known to be associated with VDD, both of which decrease 
the synthesis of the precursor (7-dehydrocholesterol) to vitamin D3. It is also 
unknown whether any individuals could be possibly taking vitamin D or calcium 
supplementation. The use of vitamin D supplementation could artificially be 
skewing the data. Both of these supplements are readily available without a 
prescription.  
 
Some of the ELISA kits proved to be poor quality, especially the PCT and CAMP 
kits. This resulted in the %CV needing to be increased to allow enough data for 
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statistical analysis. Sputum proved rather difficult to work with in ELISA tests. 
Accurate duplicates were often difficult to obtain even though no sputum dilutions 
were being performed. Inter-assay variability is a major issue with commercial 
ELISA kits. Kits produced in different lots often produce dissimilar standard 
curves. Producing an average standard curve for each analyte may have been 
beneficial when inter-assay variability is detected.  The vitamin D controls 
concentration was not provided; therefore they were only useful for assessing that 
there were no major errors with how the kit was run. Major issues with inter 
variability between laboratories has been frequently reported with vitamin D 
assays. 
 
4.9  Conclusions and Future Research 
This study provides evidence for the uneven distribution of AMP’s, vitamin D 
metabolites and procalcitonin, between systemic and localised respiratory levels 
in non-cystic fibrosis bronchiectasis. Both of the antimicrobial peptides, 
cathelicidin and β-defensin 2, showed elevated sputum levels compared to serum 
levels. This places the antimicrobial peptides at the site of the reoccurring acute 
pulmonary exacerbations in bronchiectasis. These results reflect the fact that 
bronchiectasis is a much localised disease and therefore flowover systemic effects 
are not expected. Focusing on antimicrobial peptides is important due to their 
antimicrobial capabilities, especially against antibiotic resistant bacteria.  
 
Both vitamin D metabolites, 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin 
D3, were shown to be significantly lower in sputum compared to serum. This is 
most likely due to the majority of vitamin D metabolites being protein bound 
which limits their distribution into the airways. Lastly, procalcitonin 
concentrations were not consistently elevated in the serum but were in the sputum 
of stable bronchiectasis patients. In fact procalcitonin levels were lower than those 
previously identified in other respiratory conditions. Without knowing the 
incidences of acute exacerbations, it is unknown whether procalcitonin will be a 
suitable marker for exacerbations in bronchiectasis. 
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Sub-optimal vitamin D levels are prevalent in non-cystic fibrosis bronchiectasis 
patients. Numerous papers report the association between vitamin D deficiency 
and chronic respiratory diseases. The potential reality is that vitamin D deficiency 
is a consequence of living with a respiratory condition and not a causative factor. 
The vitamin D deficiency may be due to decreased outdoor activities and 
therefore reduced sun exposure as a result of chronic respiratory disease. The only 
way direct causality can be determined is via the use of randomised controlled 
trials of vitamin D supplementation. This will reveal if increasing vitamin D status 
improves the clinical outcome. 
 
The active form, 1,25-dihydroxyvitamin D, has been shown in vitro to upregulate 
both cathelicidin and β-defensin 2. The majority of findings failed to find an 
association between vitamin D concentrations and antimicrobial peptides in vivo. 
Only CAMP and 1,25-dihydroxyvitamin D localised sputum levels showed a 
positive correlation. Future attempts at identifying this association in vivo should 
focus on the active hormone 1,25-dihydroxyvitamin D rather than the traditional 
25-hydroxyvitamin D.  
 
Other future research should focus on other factors known to influence vitamin D 
bioavailability, particularly genotyping the genes for vitamin D binding protein 
and vitamin D receptor in bronchiectasis patients. Further investigation is needed 
to identify the mechanisms behind the possible synergistic relationships found 
between cathelicidin/β-defensin 2, and β-defensin 2/procalcitonin. Focus clearly 
though needs to be on identifying the underlying mechanisms leading to the 
uneven distribution of antimicrobial peptides. Any future treatment of 
bronchiectasis needs to be focused on prevention and slowing of the progressive 
loss of lung function in bronchiectasis patients. 
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Appendices 
 
6.1  Calculation and Statistical Analysis of ELISA 
Concentrations 
ELISA concentrations are determined by curve-fitting the provided standard 
concentrations. For cathelicidin, hBD-2 and PCT the curve-fit used was a 
polynomial regression (order=2). For the vitamin D metabolites a four-parameter 
logistic curve fit is applied. The OD of each duplicate first has the blank OD 
subtracted, and then is put into the standard curve equation. The dilution factor for 
the ELISA needs to be taken into account. The dilution factor of three-fold for all 
sputum samples, resulting from the sputum processing (2.2.2), also needs to be 
factored into the concentrations. The average concentration can then be found for 
the duplicates. Duplicates are checked to ensure they are close by calculating the 
co-efficient of variation (%CV). Only duplicates that meet their respective %CV 
are included for statistical analysis. 
 
P-values are generated by a simple two-tailed student T-Test for the total samples. 
A Paired T-test is used when comparing paired sample data between visits. A P-
value of <0.05 is considered significant, so rejects the null hypothesis that the 
means of the two populations are equal. A value >0.05 indicates that the observed 
result is due to random chance.   
 
Spearman’s rank correlation coefficient (rho) enables you to identify if there is a 
monotonic relationship between two specified variables. The null hypothesis 
states that there is no association between the two variables. The closer the rho 
value is to +/- 1, the stronger this relationship. 
 
Data is log transformed to provide a more normal distribution thereby allowing 
the use of parametric tests. Cathelicidin and hBD-2 concentrations were compared 
vitamin D concentrations using tertiles as no standardised cut-off levels available. 
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6.1.1  Procalcitonin 
PCT concentrations were deduced from their respective standard curves (Figure 
39 & Figure 40) using the calculated equations. Neither serum nor sputum 
samples required dilution prior to PCT ELISA. The blank used for these samples 
was an empty well. The variation of coefficient used was <40% due to the 
difficulty in obtaining duplicates samples.   
6.1.1.1  Standard Curve Run One 
The standard curve (Figure 39) was produced using the provided standard (ELISA 
Kit for Procalcitonin; USCNK, Wuhan, China; Lot: L130118397) providing a 
concentration range from 31.2-2000pg/mL. The standard curve was fitted using a 
polynomial trend line (order=2), with the intercept set at zero. The OD value (X-
axis) is plotted against the known concentration of the standard (Y-axis). The 
calculated equation: y= 230.23x
2
 + 592.5x; R
2
=0.9719. 
 
 
Figure 39 Standard Curve for Human PCT (Run One) 
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6.1.1.2  Standard Curve Run Two 
The standard curve (Figure 40) was produced using the provided standard (ELISA 
Kit for Procalcitonin; USCNK, Wuhan, China; Lot: L130712311), providing a 
concentration range from 31.2-2000pg/mL. The standard curve was fitted using a 
polynomial trend line (order=2), with the intercept set at zero. The OD value (X-
axis) is plotted against the known concentration of the standard (Y-axis). The 
calculated equation: y= 103.04x
2
 + 558.07x; R
2
=0.9997. 
 
 
Figure 40 Standard Curve for Human PCT (Run Two) 
 
6.1.2  Hycult LL-37 ELISA 
The standard for this kit provides a concentration of 0.1-100ng/mL. The following 
standard curve (Figure 41) was created using a polynomial curve fit (order=2) 
with intercept not set at zero. The equation: y=13.168x
2
+4.3062x+0.4178 was 
used to calculate LL-37 concentration, with an R
2
 value of 0.9987. The supplied 
wash/dilution buffer was used for the blank well as used for all standard and 
sample dilutions. The concentration from the standard curve was multiplied by the 
serum dilution factor (1:20) before duplicates were averaged, only samples with 
a %CV of <15% used. 
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Figure 41 Standard Curve for Hycult LL-37 ELISA Kit 
 
6.1.3  USCNK CAMP ELISA  
Cathelicidin concentrations were deduced from their respective standard curves 
(Figure 42 & Figure 43) using the calculated equations. Serum required a 1:500 
dilution; sputum samples were diluted 1:5000 for Run One and 1:10000 for Run 
Two. The blank used for these samples was 0.01mol/L PBS (pH=7.0-7.2) as was 
used for sample dilutions. Only samples with a % CV < 30% are going to be 
considered for statistical analysis.  
6.1.3.1 Standard Curve Run One 
The standard curve (Figure 42) was produced using the provided standard (ELISA 
Kit for Cathelicidin Antimicrobial Peptide (CAMP); USCNK, Wuhan, China; Lot: 
L130205100) providing a concentration range from 125-8000pg/mL. The 
standard curve was fitted using a polynomial trend line (order=2), with the 
intercept set at zero. The OD value (X-axis) is plotted against the known 
concentration of the standard (Y-axis). The calculated equation: y= 1137.4x
2
 + 
676.25x; R
2
=0.9998.  
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Figure 42 Standard Curve for Human CAMP ELISA (Run One) 
 
6.1.3.2 Standard Curve Run Two 
The standard curve (Figure 43) was produced using the provided standard (ELISA 
Kit for Cathelicidin Antimicrobial Peptide (CAMP); USCNK, Wuhan, China; Lot: 
130712312) providing a concentration range from 125-8000pg/mL. The standard 
curve was fitted using a polynomial trend line (order=2), with the intercept set at 
zero. The OD value (X-axis) is plotted against the known concentration of the 
standard (Y-axis). The calculated equation: y= 939.23x
2
 + 39.569x; R
2
=0.9948.  
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Figure 43 Standard Curve for Human CAMP ELISA (Run Two) 
 
6.1.4  β-defensin 2 
hBD-2 concentrations were deduced from their respective standard curves (Figure 
44 & Figure 45) using the calculated equations. Both sputum and serum samples 
required no dilution for ELISA assay. The blank used for these samples was an 
empty well, as no samples had required any further dilutions. Only samples with 
a % CV < 30% are going to be considered for statistical analysis.  
6.1.4.1  Standard Curve Run One 
The standard curve (Figure 44) was produced using the provided standard (ELISA 
Kit for Defensin Beta 2; USCNK, Wuhan, China; Lot: L130205101) providing a 
concentration range from 23.44-1500pg/mL. The highest provided standard 
(3000pg/mL) was omitted from this run, as in preliminary tests it gave an OD 
reading of 6. In exchange for this standard being omitted a lower standard was 
added (23.44pg/mL) to the standard curve. The standard curve was fitted using a 
polynomial trend line (order=2), with the intercept set at zero. The OD value (X-
axis) is plotted against the known concentration of the standard (Y-axis). The 
calculated equation: y= 16.919x
2
 + 362.06x; R
2
=0.9985.  
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Figure 44 Standard Curve for hBD-2 (Run One) 
 
6.1.4.2  Standard Curve Run Two 
The standard curve (Figure 45) was produced using the provided standard (ELISA 
Kit for Defensin Beta 2; USCNK, Wuhan, China; Lot: L130712312), providing a 
concentration range from 46.88-3000pg/mL. An outlier in the data, OD for 
750pg/mL, was omitted from the standard curve. The standard curve was fitted 
using a polynomial trend line (order=2), with the intercept set at zero. The OD 
value (X-axis) is plotted against the known concentration of the standard (Y-axis). 
The calculated equation: y= 99.733x
2
 + 412.22x; R
2
=0.9975. 
 
Only a quality control was provided with the ELISA kit used for run two (ELISA 
Kit for Defensin Beta 2; USCNK, Wuhan, China; Lot: L130712312). The quality 
control measured was 741.88pg/mL. The expected quality control concentration 
was 540.10pg/mL. The %CV between the observed and expected quality control 
concentration was 22.26%. 
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Figure 45 Standard Curve for hBD-2 (Run Two) 
 
6.1.5 Vitamin D 
The 25(OH)D3 and 1,25(OH)2D3 concentration has been analysed using a 
competitive inhibition enzyme immunoassay technique. This type of ELISA 
requires a non-linear regression for the standard curve to determine samples 
concentration. The suggested curve-fit was a four-parameter logistic model based 
on the following equation: 
                                                  
Concentrations are determined by back-fitting to find x (x=(((((B-A)/(y-A))-
1)^(1/D))*C)).  
6.1.5.1 25-hydroxyvitamin D3 
The dilution factor of 1:30 for serum needs to be taken into account and 
multiplied by the concentration off the standard curve. The supplied standard 
(Human 25-dihydroxyvitamin D3 ELISA Kit, CUSABIO, Wuhan, China; Lot: 
C603130121 & C0724300628) provides a concentration range from 0-100ug/L. 
The suggested blank used for these samples was a blank well with no solutions 
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added. Only sample duplicates with a %CV of less than 30% were included for 
analysis.  
 
Figure 46 Standard Curve for Human 25(OH)D3 (Run One) 
The four parameters from Figure 46 are: A=-0.5518, B=-0.8099, C=27.43 and 
D=2.737 with an R
2
 value of 1. The two control values: MVC – 43.07μg/L and 
HVC - 74.33μg/L.  
 
Figure 47 Standard Curve for Human 25(OH)D3 (Run Two) 
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The four parameters from Figure 47 are: A=-0.1681, B=-0.7829, C=10.55 and 
D=2.734 with an R
2
 value of 1. The two control values: MVC – 45.84μg/L and 
HVC – 69.49μg/L. 
 
No actual concentrations were provided for the 25(OH)D controls. The %CV of 
the MVC’s was 4.41% for between the two assay runs. The %CV of the HVC’s 
was 4.76% for between the two assay runs.  
 
6.1.5.2  1,25-dihydroxyvitamin D3 
The dilution factor of 1:10 for serum needs to be taken into account and 
multiplied by the concentration off the standard curve. The supplied standard 
(Human 1,25-dihydroxyvitamin D3 ELISA Kit, CUSABIO, Wuhan, China; Lot: 
C603120903 & C603130422) provides a concentration range from 0-5000fmol/L. 
The suggested blank used for these samples was a blank well with no solutions 
added. Only sample duplicates with a %CV of less than 30% were included for 
analysis.  
 
 
Figure 48 Standard Curve for Human 1,25(OH)2D3 (Run One) 
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The four parameters from Figure 48 are: A=0.0608, B=-1.735, C=1815 and 
D=2.754 with an R
2
 value of 0.9971. The two control values: MVC – 2779fmol/L 
and HVC – 5901fmol/L.  
 
 
Figure 49 Standard Curve for Human 1,25(OH)2D3 (Run Two) 
The four parameters from Figure 49 are: A=-1.659, B=-0.7945, C=3849, D=2.732 
with an R
2
 value of 1. For this standard curve the data point for the 1000fmol/L 
concentration was excluded to improve the curve fit at the lower optical densities. . 
The two control values: MVC – 2924fmol/L and HVC – 4960fmol/L.  
 
No actual concentrations were provided for the 1,25(OH)2D controls. The %CV 
of the MVC’s was 3.60% for between the two assay runs. The %CV of the HVC’s 
was 12.25% for between the two assay runs.  
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6.2  ELISA Results 
 
Table 9 Serum ELISA Concentrations 
Visit 25(OH)D3 
(nmol/L) 
1,25(OH)2D3 
(pmol/L) 
hBD-2 
(pg/mL) 
LL-37 
(ng/mL) 
CAMP 
(ng/mL) 
PCT 
(pg/mL) 
1 31.95 23.70 107.07 51.98 1440.68 29.25 
5 - 26.24 32.85 53.84 - 17.09 
6 67.93 46.08 49.47 52.18 - - 
9 32.98 33.15 38.55 40.52 - - 
1 50.82 35.90 137.23 49.96 643.67 - 
5 36.93 36.14 48.99 41.19 - 20.56 
6 80.33 62.41 73.41 47.50 1632.89 13.27 
9 40.16 53.30 79.92 38.56 - - 
1 65.84 36.25 67.69 60.13 543.06 32.52 
5 42.47 29.82 46.63 59.35 - 19.63 
6 104.06 61.15 36.67 64.26 324.36 9.84 
9 61.00 49.26 30.73 56.48 - - 
1 44.52 63.61 25.02 97.29 302.29 13.03 
5 - 33.67 26.64 137.49 - - 
6 90.05 70.12 25.43 120.15 227.54 - 
9 46.80 51.47 8.05 113.62 - 15.20 
1 90.83 55.20 325.00 33.13 692.12 73.34 
5 24.59 28.72 217.45 32.01 - 55.27 
6 88.66 70.63 172.45 36.10 - 39.33 
9 93.94 45.24 153.97 - - 65.60 
1 66.65 52.99 124.46 39.72 409.87 41.11 
5 - 34.66 33.17 55.88 401.06 18.96 
6 97.04 81.93 79.12 37.18 1315.47 - 
9 - 44.69 43.26 - - 25.69 
1 27.42 24.49 101.08 86.45 542.33 83.10 
5 28.21 13.17 173.56 65.19 1760.61 153.92 
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6 19.21 21.43 93.94 - - - 
9 35.01 19.92 93.89 - - 22.32 
1 108.33 69.07 91.06 61.30 295.63 27.10 
5 49.08 36.73 248.73 70.10 710.40 68.67 
6 97.26 94.57 94.13 - - 42.04 
9 129.59 40.21 183.10 - - 16.44 
1 75.69 34.03 18.75 50.91 415.47 24.66 
5 65.93 32.82 217.72 45.73 - 733.08 
6 97.18 76.94 35.72 - - - 
9 77.73 31.55 33.77 - - 15.54 
1 74.49 81.75 21.66 33.36 669.63 141.79 
5 80.05 62.08 66.24 25.91 860.73 10.02 
6 93.38 64.95 44.46 - 164.98 - 
9 60.75 27.52 22.18 - - 14.78 
1 63.74 - - - - 142.75 
5 81.37 44.96 65.19 - 693.52 - 
6 79.49 46.90 - - - - 
1 48.40 61.46 116.57 23.35 264.65 70.66 
5 - - 154.28 23.32 285.26 - 
1 68.11 63.97 219.82 24.82 156.33 179.79 
5 78.19 46.17 233.21 27.53 - - 
6 71.31 53.50 51.08 - 89.41 9.26 
9 56.73 28.84 45.04 - - - 
1 102.81 67.86 - 127.36 245.02 103.18 
5 - - 109.36 107.42 290.44 - 
5 - - 72.35 - 341.49 - 
1 83.56 65.70 - - 653.45 47.71 
5 - - 52.24 - 816.49 - 
1 91.24 59.29 144.67 - 256.82 - 
5 - - - - - 12.09 
1 76.55 76.76 72.04 - - 71.91 
5 - - 59.41 - - - 
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5 - - - - - 8.22 
1 - 54.59 110.82 - - - 
5 - 53.93 230.08 - 590.95 26.39 
1 105.61 - 266.42 48.37 175.32 35.09 
5 83.21 - - 46.79 - 28.06 
6 69.03 74.45 - - - - 
 
Table 10 Sputum ELISA Concentrations 
Visit 25(OH)D3 
(nmol/L) 
1,25(OH)2D3 
(pmol/L) 
hBD-2 
(pg/mL) 
CAMP 
(μg/mL) 
PCT 
(pg/mL) 
1 19.12 19.07 201.47 - - 
5 24.11 18.10 93.35 - 128.68 
6 23.55 18.18 328.19 196.55 252.23 
9 19.24 17.46 376.69 - 338.59 
1 13.63 12.22 107.99 40.68 510.55 
5 16.14 14.24 1090.66 - 697.48 
6 9.44 12.66 2121.03 - 653.03 
9 11.70 11.76 1493.29 93.09 690.67 
1 13.43 11.58 38.68 62.40 60.64 
5 24.91 18.10 46.04 - 205.71 
6 24.11 16.17 275.08 - 282.21 
9 14.41 14.49 137.45 133.75 278.19 
1 6.00 14.03 96.64 - 176.91 
5 11.43 31.98 178.01 - 151.68 
6 21.79 17.60 149.83 - 393.26 
9 31.88 17.41 73.56 - 132.44 
1 9.38 14.36 68.69 64.06 131.75 
5 19.56 39.18 103.43 115.24 139.45 
6 27.52 15.25 157.82 63.83 211.39 
9 21.39 13.49 574.20 - 753.04 
1 18.23 15.16 65.58 35.61 78.66 
5 19.95 13.15 262.28 18.18 228.71 
 115 
 
6 16.09 8.38 376.02 142.34 280.49 
9 16.92 12.25 262.96 - - 
1 6.68 7.38 74.65 - - 
5 - - 89.57 44.92 170.08 
6 25.94 10.39 136.23 58.09 178.77 
9 13.91 11.08 170.85 - 166.61 
1 11.12 - 43.86 55.73 - 
5 11.20 9.98 72.24 76.09 167.49 
6 12.11 10.84 149.77 - 145.20 
9 15.63 9.45 749.44 - 530.47 
1 11.60 5.81 90.50 - 248.26 
5 4.83 8.99 150.11 46.31 223.03 
6 4.91 10.07 211.11 - 297.82 
9 7.82 7.25 405.46 41.66 - 
1 19.82 8.37 146.25 23.97 - 
5 9.91 7.79 81.84 - 176.33 
6 - 8.09 56.95 - - 
9 9.03 7.02 262.69 21.37 252.02 
1 13.40 15.77 - 76.00 - 
1 14.40 21.14 57.66 145.18 499.80 
5 - 9.19 - - - 
1 7.61 14.78 94.88 5.64 247.54 
5 9.25 8.45 276.77 - 394.91 
6 8.54 8.18 100.66 5.70 229.46 
9 6.93 6.39 192.91 - 194.02 
1 17.15 16.60 79.84 - 246.30 
1 28.25 42.96 - 61.33 164.21 
1 20.42 19.94 50.40 - 114.26 
1 - 4.23 - 2.17 133.92 
1 22.00 - - - 81.57 
1 - - - - 152.22 
5 - - 36.23 - - 
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1 0.58 0.82 152.54 - 570.89 
1 17.83 - - - 104.33 
1 - - 30.07 - 195.43 
1 - - 129.76 1.48 360.72 
1 12.36 - 56.57 0.61 119.02 
 
 
 
